Journal ArticleAm Heart J · January 2025
BACKGROUND: While there are several completed clinical trials that address treatment strategies in patients with symptomatic and recurrent atrial fibrillation (AF), there are no randomized clinical trials that address first-line rhythm control of new-onset ...
Full textLink to itemCite
Journal ArticleHeart Rhythm · December 2024
BACKGROUND: In patients with a history of stroke or those at high risk for developing stroke, a continuous rhythm monitoring strategy using an implantable loop recorder (ILR) is often performed to screen for atrial fibrillation (AF). OBJECTIVES: The purpos ...
Full textLink to itemCite
Journal ArticleJAMA · November 26, 2024
IMPORTANCE: The emergence of novel programming guidelines that reduce premature and inappropriate therapies along with the availability of new implantable cardioverter-defibrillator (ICD) technologies lacking traditional endocardial antitachycardia pacing ...
Full textLink to itemCite
Journal ArticleJ Am Heart Assoc · November 22, 2024
BACKGROUND: Left atrial appendage occlusion (LAAO) is increasingly used as an alternative to oral anticoagulation for stroke prevention in select patients with atrial fibrillation. Data on outcomes in racial and ethnic minority individuals are limited. Thi ...
Full textLink to itemCite
Journal ArticleHeart Rhythm · November 18, 2024
BACKGROUND: Binding sites in the costoclavicular space are commonly encountered during transvenous lead extraction. Severe adhesions may warrant use of more aggressive rotational cutting tools or surgical intervention. It is not known whether preprocedural ...
Full textLink to itemCite
Journal ArticleAm J Cardiol · November 8, 2024
Pulmonary vein isolation (PVI) has been established as a first-line therapy for symptomatic atrial fibrillation (AF) in selected patients with symptomatic AF and in those whose antiarrhythmic drug treatment failed. However, AF recurrence rates after PVI re ...
Full textLink to itemCite
Journal ArticleHeart Rhythm · November 6, 2024
BACKGROUND: The first commercial systems for pulsed field ablation (PFA) were recently approved by the Food and Drug Administration, but their safety profile in nationwide practice remains underexplored. OBJECTIVES: This study aimed to describe reported ad ...
Full textLink to itemCite
Journal ArticleJACC. Clinical electrophysiology · November 2024
BackgroundMost clinical trials define successful atrial fibrillation (AF) treatment as no AF episodes longer than 30 seconds. Yet, there has been minimal study of how patients define successful treatment and whether their perspectives align with t ...
Full textCite
Journal ArticleHeart Rhythm O2 · November 1, 2024
Background: There have been limited data examining the temporal relationship between device-derived daily activity and ventricular arrhythmias (VAs). Objective: We aimed to assess whether activity predicted VAs or VAs predicted changes in activity. Methods ...
Full textCite
Journal ArticleJACC Adv · November 2024
BACKGROUND: Despite clear associations between arrhythmia burden and cardiovascular risk, clinical risk scores that predict cardiovascular events do not incorporate individual-level arrhythmia characteristics from long-term continuous monitoring (LTCM). OB ...
Full textLink to itemCite
Journal ArticleCirc Arrhythm Electrophysiol · November 2024
BACKGROUND: Atrial fibrillation is associated with an increased risk of cardiovascular hospitalization (CVH), which may be triggered by changes in daily burden. Machine learning of dynamic trends in atrial fibrillation burden, as measured by insertable car ...
Full textLink to itemCite
Journal ArticleCirc Arrhythm Electrophysiol · November 2024
BACKGROUND: Atrial fibrillation (AF) is associated with an increased risk of stroke, yet the limitations of conventional monitoring have restricted our understanding of AF burden risk thresholds. Predictive algorithms incorporating continuous AF burden mea ...
Full textLink to itemCite
Journal ArticleEuropace · November 1, 2024
AIMS: Leadless pacing is a safe and effective alternative to transvenous pacing for bradycardia. Micra AV is a leadless, single-device solution that provides atrioventricular synchronous ventricular pacing therapy. Early results from the Micra AV CED study ...
Full textLink to itemCite
Journal ArticleHeart Rhythm · October 24, 2024
BACKGROUND: Practice guidelines recommend ablation (ABL) in atrial fibrillation (AF) for rhythm control. Guidance for antiarrhythmic drugs (AADs) post-ABL is limited. OBJECTIVE: The purpose of this study was to determine AAD and ABL practices in the United ...
Full textLink to itemCite
Journal ArticleJ Cardiovasc Electrophysiol · October 15, 2024
INTRODUCTION: Conduction system pacing (CSP), often accomplished with lumenless pacing leads, is increasingly employed to achieve physiologic ventricular activation. There are limited data on the extraction of these leads. The objective of this study was t ...
Full textLink to itemCite
Journal ArticleHeart Rhythm · October 2024
BACKGROUND: Advances in leadless pacemaker technology have enabled accelerometer-based atrioventricular (AV) synchronous pacing by sensing atrial mechanical contraction. OBJECTIVE: The purpose of this study was to report the performance of the Micra AV lea ...
Full textLink to itemCite
Journal ArticleESC Heart Fail · September 10, 2024
AIMS: One treatment option for refractory ventricular arrythmias is stellate ganglion block (SGB). We examined differences in SGB success by patient and arrhythmia characteristics and predictors of successful SGB. METHODS AND RESULTS: This was a multicente ...
Full textLink to itemCite
Journal ArticleJ Am Coll Cardiol · September 3, 2024
BACKGROUND: The prevalence of and outcomes associated with different antithrombotic strategies after left atrial appendage occlusion (LAAO) are not well described. OBJECTIVES: This study sought to evaluate patterns of antithrombotic medication strategies a ...
Full textLink to itemCite
Journal ArticleHeart Rhythm · September 2024
In the last three decades, ablation of atrial fibrillation (AF) has become an evidence-based safe and efficacious treatment for managing the most common cardiac arrhythmia. In 2007, the first joint expert consensus document was issued, guiding healthcare p ...
Full textLink to itemCite
Journal ArticleJ Cardiovasc Electrophysiol · September 2024
INTRODUCTION: The impact of mRNA-based coronavirus disease-2019 (COVID-19) vaccines on atrial arrhythmias (AA) and ventricular arrhythmias incidence is unknown. METHODS: BIOTRONIK Home Monitoring data and Medicare Claims data were utilized to identify indi ...
Full textLink to itemCite
Journal ArticleCirc Cardiovasc Interv · September 2024
BACKGROUND: PINNACLE FLX (Protection Against Embolism for Nonvalvular AF Patients: Investigational Device Evaluation of the WATCHMAN FLX LAA Closure Technology) demonstrated improved outcomes and low incidence of adverse events with the WATCHMAN FLX device ...
Full textLink to itemCite
Journal ArticleJ Am Heart Assoc · August 6, 2024
BACKGROUND: Shock-reduction implantable cardioverter-defibrillator programming (SRP) was associated with fewer therapies and improved survival in randomized controlled trials, but real-world studies investigating SRP and associated outcomes are limited. ME ...
Full textLink to itemCite
Journal ArticleJ Interv Card Electrophysiol · August 2024
In the last three decades, ablation of atrial fibrillation (AF) has become an evidence-based safe and efficacious treatment for managing the most common cardiac arrhythmia. In 2007, the first joint expert consensus document was issued, guiding healthcare p ...
Full textLink to itemCite
Journal ArticleJACC Clin Electrophysiol · August 2024
BACKGROUND: New-onset atrial fibrillation (NOAF) occurs in 5% to 15% of patients who undergo transfemoral transcatheter aortic valve replacement (TAVR). Cardiac imaging has been underutilized to predict NOAF following TAVR. OBJECTIVES: The objective of thi ...
Full textLink to itemCite
Journal ArticleHeart Rhythm · July 23, 2024
BACKGROUND: Implantable cardioverter-defibrillator (ICD) shocks are a common complication after left ventricular assist device (LVAD) implantation; however, data on their frequency and causes are limited. OBJECTIVE: The purpose of this study was to define ...
Full textLink to itemCite
Journal ArticleHeart Rhythm · July 2024
BACKGROUND: Loading of oral sotalol for atrial fibrillation requires 3 days, frequently in the hospital, to achieve steady state. The Food and Drug Administration approved loading with intravenous (IV) sotalol through model-informed development, without pa ...
Full textLink to itemCite
Journal ArticleJ Am Heart Assoc · June 4, 2024
BACKGROUND: Days alive out of hospital (DAOH) is an objective and patient-centered net benefit end point. There are no assessments of DAOH in clinical trials of interventions for atrial fibrillation (AF), and it is not known whether this end point is of cl ...
Full textLink to itemCite
Journal ArticleCirc Cardiovasc Interv · June 2024
BACKGROUND: Procedure volumes are associated with outcomes for many cardiovascular procedures, leading to guidelines on minimum volume thresholds for certain procedures; however, the volume-outcome relationship with left atrial appendage occlusion is poorl ...
Full textLink to itemCite
Journal ArticleJ Am Heart Assoc · May 7, 2024
BACKGROUND: Obstructive sleep apnea (OSA) contributes to the generation, recurrence, and perpetuation of atrial fibrillation, and it is associated with worse outcomes. Little is known about the economic impact of OSA therapy in atrial fibrillation. This re ...
Full textLink to itemCite
Journal ArticleJ Cardiovasc Electrophysiol · May 2024
INTRODUCTION: Peak frequency (PF) mapping is a novel method that may identify critical portions of myocardial substrate supporting reentry. The aim of this study was to describe and evaluate PF mapping combined with omnipolar voltage mapping in the identif ...
Full textLink to itemCite
Journal ArticleCirc Arrhythm Electrophysiol · May 2024
BACKGROUND: Clinically detected atrial fibrillation (AF) is associated with a significant increase in mortality and other adverse cardiovascular events. Since the advent of effective methods for AF rhythm control, investigators have attempted to determine ...
Full textOpen AccessLink to itemCite
Journal ArticleJACC Clin Electrophysiol · May 2024
BACKGROUND: Postoperative atrial fibrillation (POAF) is associated with increased morbidity and mortality. Epicardial injection of botulinum toxin may suppress POAF. OBJECTIVES: This study sought to assess the safety and efficacy of AGN-151607 for the prev ...
Full textLink to itemCite
Journal ArticleEur Heart J · April 7, 2024
BACKGROUND AND AIMS: Prior reports have demonstrated a favourable safety and efficacy profile of the Micra leadless pacemaker over mid-term follow-up; however, long-term outcomes in real-world clinical practice remain unknown. Updated performance of the Mi ...
Full textLink to itemCite
Journal ArticleHeart Rhythm · April 2024
Catheter ablation of atrial fibrillation (AF) is an established therapy that reduces AF burden, improves quality of life, and reduces the risks of cardiovascular outcomes. Although there are clear guidelines for the application of de novo catheter ablation ...
Full textLink to itemCite
Journal ArticleAm Heart J · April 2024
BACKGROUND: The finding of unexpected variations in treatment benefits by geographic region in international clinical trials raises complex questions about the interpretation and generalizability of trial findings. We observed such geographical variations ...
Full textOpen AccessLink to itemCite
Journal ArticleJACC Clin Electrophysiol · April 2024
BACKGROUND: Ventricular tachycardia (VT) and ventricular fibrillation (VF) are life-threatening conditions and can be refractory to conventional drug and device interventions. Stellate ganglion blockade (SGB) has been described as an adjunct, temporizing i ...
Full textLink to itemCite
Journal ArticleEuropace · March 30, 2024
In the last three decades, ablation of atrial fibrillation (AF) has become an evidence-based safe and efficacious treatment for managing the most common cardiac arrhythmia. In 2007, the first joint expert consensus document was issued, guiding healthcare p ...
Full textLink to itemCite
Journal ArticleJ Interv Card Electrophysiol · March 18, 2024
BACKGROUND: Cardioneuroablation has been emerging as a potential treatment alternative in appropriately selected patients with cardioinhibitory vasovagal syncope (VVS) and functional AV block (AVB). However the majority of available evidence has been deriv ...
Full textLink to itemCite
Journal ArticleJ Am Coll Cardiol · February 13, 2024
BACKGROUND: Phase II trials of asundexian were underpowered to detect important differences in bleeding. OBJECTIVES: The goal of this study was to obtain best estimates of effects of asundexian vs active control/placebo on major and clinically relevant non ...
Full textLink to itemCite
Journal ArticleEuropace · February 1, 2024
AIMS: Different disease processes can combine to cause atrial fibrillation (AF). Their contribution to recurrent AF after ablation in patients is not known. Cardiovascular processes associated with recurrent AF after AF ablation were determined by quantify ...
Full textLink to itemCite
Journal ArticleHeart Rhythm O2 · February 2024
BACKGROUND: Cerebral microembolization and atrophy complicate atrial fibrillation (AF). OBJECTIVES: We aimed to compare changes in neuroimaging findings between AF patients treated with catheter ablation and those treated with medical therapy. METHODS: In ...
Full textLink to itemCite
Journal ArticleCirculation · January 2, 2024
AIM: The "2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation" provides recommendations to guide clinicians in the treatment of patients with atrial fibrillation. METHODS: A comprehensive literature search was conducted ...
Full textLink to itemCite
Journal ArticleJ Am Coll Cardiol · January 2, 2024
AIM: The "2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Patients With Atrial Fibrillation" provides recommendations to guide clinicians in the treatment of patients with atrial fibrillation. METHODS: A comprehensive literature search ...
Full textLink to itemCite
Journal ArticleHeart Rhythm · January 2024
BACKGROUND: Atrial fibrillation (AF) can be a cause and consequence of cardiac remodeling. The natural history of remodeling associated with AF is incompletely described. OBJECTIVE: The purpose of this study was to describe the frequency and timing of AF-a ...
Full textLink to itemCite
Journal ArticleHeart Rhythm · January 2024
BACKGROUND: The Micra AV Coverage with Evidence Development study is a novel analysis of utilization and outcomes associated with Micra AV leadless pacing in US Medicare patients. OBJECTIVE: The purpose of this study was to describe patient characteristics ...
Full textLink to itemCite
Journal ArticleHeart Rhythm O2 · January 2024
BACKGROUND: Leadless pacemakers represent a paradigm-changing advancement. However, they required innovative and novel device design, including the use of nitinol tines for fixation. OBJECTIVE: We aimed to understand the potential for fracture in the novel ...
Full textLink to itemCite
Journal ArticleJournal of Arrhythmia · January 1, 2024
In the last three decades, ablation of atrial fibrillation (AF) has become an evidence-based safe and efficacious treatment for managing the most common cardiac arrhythmia. In 2007, the first joint expert consensus document was issued, guiding healthcare p ...
Full textCite
Journal ArticleHeart Rhythm O2 · January 1, 2024
Background: Atrial fibrillation (AF) has a significant impact on health and quality of life. The relationship of AF burden and temporal patterns of AF on patient symptoms, outcomes, and healthcare utilization is unknown. Insertable cardiac monitors (ICMs) ...
Full textCite
Journal ArticleEuropace · December 6, 2023
AIMS: Left atrial catheter ablation is well established in patients with symptomatic atrial fibrillation (AF) but associated with risk of embolism to the brain. The present analysis aims to assess the impact of diffusion-weighted imaging (DWI) slice thickn ...
Full textLink to itemCite
Journal ArticleJACC Clin Electrophysiol · December 2023
BACKGROUND: Intraprocedural imaging is critical for device delivery in transcatheter left atrial appendage occlusion (LAAO). Although pivotal trials of LAAO devices were conducted using transesophageal echocardiography (TEE), intracardiac echocardiography ...
Full textLink to itemCite
Journal ArticleJAMA Neurol · December 1, 2023
IMPORTANCE: The STROKE AF study found that in patients with prior ischemic stroke attributed to large-artery atherosclerotic disease (LAD) or small-vessel occlusive disease (SVD), 12% developed AF over 1 year when monitored with an insertable cardiac monit ...
Full textLink to itemCite
Journal ArticleJAMA Cardiol · December 1, 2023
IMPORTANCE: Complete hardware removal is a class I recommendation for cardiovascular implantable electronic device (CIED) infection, but practice patterns and outcomes remain unknown. OBJECTIVE: To quantify the number of Medicare patients with CIED infecti ...
Full textLink to itemCite
Journal ArticleJ Arrhythm · December 2023
BACKGROUND: Traditional risk scores for recurrent atrial fibrillation (AF) following catheter ablation utilize readily available clinical and echocardiographic variables and yet have limited discriminatory capacity. Use of data from cardiac imaging and dee ...
Full textLink to itemCite
Journal ArticleCirc Cardiovasc Qual Outcomes · December 2023
BACKGROUND: Among patients hospitalized for atrial fibrillation, the frequency of off-label direct oral anticoagulant (DOAC) dosing, associated factors, hospital-level variation, and temporal trends in contemporary practice are unknown. METHODS: Using the ...
Full textLink to itemCite
Journal ArticleJACC Cardiovasc Interv · November 27, 2023
BACKGROUND: Left atrial appendage occlusion (LAAO) is an approved alternative for stroke prevention in atrial fibrillation for patients with an "appropriate rationale" to avoid long-term oral anticoagulation (OAC). Many patients undergoing LAAO are at high ...
Full textLink to itemCite
Journal ArticleAm J Cardiol · November 15, 2023
Atrial fibrillation (AF) practice guidelines recommend a rhythm-control strategy to improve symptoms and quality of life, noting the side effects of antiarrhythmic drugs and catheter ablation. Emerging evidence indicates that comprehensive early rhythm con ...
Full textLink to itemCite
Journal ArticleClin Cardiol · November 2023
BACKGROUND: An unmet need exists to reliably predict the risk of intracranial hemorrhage (ICH) in patients with atrial fibrillation (AF) treated with oral anticoagulants (OACs). HYPOTHESIS: An externally validated model improves ICH risk stratification. ME ...
Full textLink to itemCite
Journal ArticleJ Cardiovasc Electrophysiol · November 2023
BACKGROUND: Traditional transvenous pacemakers are associated with worsening tricuspid valve function due to lead-related leaflet impingement, as well as ventricular dysfunction related to electromechanical dyssynchrony from chronic right ventricular (RV) ...
Full textLink to itemCite
Journal ArticleAm J Cardiovasc Drugs · November 2023
BACKGROUND: There is evidence to suggest that colchicine reduces the risk of recurrent atrial fibrillation (AF) after catheter ablation; however, the tolerability and safety of colchicine in routine practice is unknown. METHODS: Patients undergoing cathete ...
Full textLink to itemCite
Journal ArticleHeart Rhythm · October 2023
BACKGROUND: Left ventricular (LV) lead implantation is often the most challenging aspect of cardiac resynchronization therapy (CRT) procedures; early studies reported implant failure rates in ∼10% of cases. OBJECTIVE: The purpose of this study was to defin ...
Full textLink to itemCite
Journal ArticleAm J Cardiol · October 1, 2023
Cardiac sarcoidosis (CS) is a relapsing-remitting disease, and immune suppression (IS) is the mainstay of therapy. Predictors of relapse for patients with CS in remission are not well characterized. We assessed incidence of relapse in consecutive patients ...
Full textLink to itemCite
Journal ArticleCirculation · September 19, 2023
BACKGROUND: Current clinical decision tools for assessing bleeding risk in individuals with atrial fibrillation (AF) have limited performance and were developed for individuals treated with warfarin. This study develops and validates a clinical risk score ...
Full textLink to itemCite
Journal ArticleJ Am Coll Cardiol · September 5, 2023
Atrial fibrillation is the most common atrial arrhythmia and accounts for a significant burden of cardiovascular disease globally. With advances in implanted and wearable cardiac monitoring technology, it is now possible to readily and accurately quantify ...
Full textLink to itemCite
Journal ArticlePacing Clin Electrophysiol · September 2023
BACKGROUND: Leadless pacemakers have been developed to avoid some of the complications that are associated transvenous pacemakers. Pericardial effusion is a rare complication of leadless pacemaker implantation, which may result from perforation of the deli ...
Full textLink to itemCite
Journal ArticleEuropace · August 25, 2023
AIMS: Cardiac pacing represents a key element in the field of electrophysiology and the treatment of conduction diseases. Since the first issue published in 1999, EP Europace has significantly contributed to the development and dissemination of the researc ...
Full textLink to itemCite
Journal ArticleEuropace · August 2, 2023
AIMS: After an ischaemic stroke, atrial fibrillation (AF) detection allows for improved secondary prevention strategies. This study aimed to compare AF detection and oral anticoagulant (OAC) initiation in patients with an insertable cardiac monitor (ICM) v ...
Full textLink to itemCite
Journal ArticleLancet · July 8, 2023
BACKGROUND: Etripamil is a fast-acting, intranasally administered calcium-channel blocker in development for on-demand therapy outside a health-care setting for paroxysmal supraventricular tachycardia. We aimed to evaluate the efficacy and safety of etripami ...
Full textLink to itemCite
Journal ArticleJ Cardiovasc Electrophysiol · July 2023
INTRODUCTION: Accurate localization of septal outflow tract premature ventricular contractions (PVCs) is often difficult due to frequent mid-myocardial or protected origin. Compared with traditional activation mapping, CARTO Ripple mapping provides visuali ...
Full textLink to itemCite
Journal ArticleHeart Rhythm O2 · July 2023
BACKGROUND: High-power, short-duration (HPSD) radiofrequency ablation (RFA) reduces procedure time; however, safety and efficacy thresholds vary with catheter design. OBJECTIVE: The study sought to determine optimal HPSD ablation conditions with a novel fl ...
Full textLink to itemCite
Journal ArticleEuropace · June 2, 2023
AIMS: Atrial fibrillation (AF) is the most common sustained arrhythmia encountered in clinical practice. Episodes may stop spontaneously (paroxysmal AF); may terminate only via intervention (persistent AF); or may persist indefinitely (permanent AF) (see E ...
Full textLink to itemCite
Journal ArticleHeart Rhythm · June 2023
BACKGROUND: Rates of early mortality and complications after catheter ablation (CA) of atrial fibrillation (AF) vary across health care settings. OBJECTIVE: The purpose of this study was to identify the rate and predictors of early mortality (within 30 day ...
Full textLink to itemCite
Journal ArticleCirc Arrhythm Electrophysiol · June 2023
BACKGROUND: Rotational cutting tools are increasingly used in transvenous lead extraction. There are limited data on their safety and efficacy, particularly when used adjunctively for stalled progression. The aim of this study was to evaluate the utilizati ...
Full textLink to itemCite
Journal ArticleHeart Rhythm O2 · May 2023
BACKGROUND: Catheter ablation is recommended for the treatment of symptomatic atrial fibrillation (AF) refractory to medical therapy. OBJECTIVE: The study sought to examine racial/ethnic and sex differences in complications and AF/atrial flutter (AFL)-rela ...
Full textLink to itemCite
Journal ArticleJ Am Coll Cardiol · April 4, 2023
Infection remains a serious complication associated with the cardiac implantable electronic devices (CIEDs), leading to substantial clinical and economic burden globally. This review assesses the burden of cardiac implantable electronic device infection (C ...
Full textLink to itemCite
Journal ArticleStroke · April 2023
BACKGROUND: Carotid stenosis is thought to be the primary risk factor for central retinal artery occlusion (CRAO); however, it is not known whether atrial fibrillation (AF)-a cardiac arrhythmia that underlies over 25% of cerebral ischemic strokes-predispos ...
Full textLink to itemCite
Journal ArticleJ Cardiovasc Electrophysiol · April 2023
INTRODUCTION: Although atrial fibrillation (AF) ablation has become increasingly safer, rehospitalization and emergency department (ED) evaluations can occur in the postablation period. Better understanding of the frequency, causes, and predictors for hosp ...
Full textLink to itemCite
Journal ArticleJ Cardiovasc Electrophysiol · April 2023
INTRODUCTION: The Micra Coverage with Evidence Development (CED) Study is a novel comparative analysis of Micra (leadless VVI) and transvenous single-chamber ventricular pacemakers (transvenous VVI) using administrative claims data. To compare chronic comp ...
Full textLink to itemCite
Journal ArticleJ Am Heart Assoc · March 21, 2023
Background Nonvitamin K oral anticoagulants require dose adjustment based on kidney function.The most common estimate of kidney function employed in clinical practice is estimated glomerular filtration rate (eGFR); however, product monographs recommend the ...
Full textLink to itemCite
Journal ArticleEur Heart J · March 21, 2023
Postoperative atrial fibrillation (POAF) is the most common type of secondary atrial fibrillation (AF) and despite progress in prevention and treatment, remains an important clinical problem for patients undergoing a variety of surgical procedures, and in ...
Full textLink to itemCite
Journal ArticleHeart Rhythm · March 2023
BACKGROUND: Alert-driven remote patient monitoring (RPM) or fully virtual care without routine evaluations may reduce clinic workload and promote more efficient resource allocation, principally by diminishing nonactionable patient encounters. OBJECTIVE: Th ...
Full textLink to itemCite
Journal ArticleCurr Probl Cardiol · March 2023
While heart rate variability (HRV) is an established marker of cardiovascular health, the extent to which continuously measured HRV changes over time and the relationship between these changes and clinical outcomes are less clear. We performed a health sys ...
Full textLink to itemCite
Journal ArticleHeart Rhythm O2 · March 2023
BACKGROUND: There are limited data on trends in nationwide cardiac electrophysiology (EP) procedures in the United States before and during the global COVID-19 pandemic. OBJECTIVE: We aimed to understand contemporary EP procedural trends and how the COVID- ...
Full textLink to itemCite
Journal ArticleJ Am Coll Cardiol · February 28, 2023
Factor XI/XIa (FXI/FXIa) represents a potential target for improved precision in anticoagulation because it is involved primarily in thrombus formation and plays a much smaller role in clotting and hemostasis. This suggests that the inhibition of FXI/XIa c ...
Full textLink to itemCite
Journal ArticleJ Am Heart Assoc · February 7, 2023
Background Oral anticoagulation reduces stroke and disability in atrial fibrillation (AF) but is underused. We evaluated the effects of a novel patient-clinician shared decision-making (SDM) tool in reducing oral anticoagulation patient's decisional confli ...
Full textLink to itemCite
Journal ArticleHeart Rhythm · January 2023
Atrial fibrillation has a multifactorial pathophysiology influenced by cardiac autonomic innervation. Both sympathetic and parasympathetic influences are profibrillatory. Innovative therapies targeting the neurocardiac axis include catheter ablation or pha ...
Full textLink to itemCite
Journal ArticleJ Cardiovasc Electrophysiol · January 2023
INTRODUCTION: Micra atrioventricular (AV) provides leadless atrioventricular synchronous pacing by sensing atrial contraction (A4 signal). Real-world operation and reliability of AV synchrony (AVS) assessment using device data have not been described. The ...
Full textOpen AccessLink to itemCite
Journal ArticleEur J Heart Fail · January 2023
AIMS: Although atrial fibrillation (AF) frequently coexists with heart failure with preserved ejection fraction (HFpEF), few data are available evaluating AF-specific care patterns and post-discharge outcomes in patients hospitalized for HFpEF. We evaluate ...
Full textLink to itemCite
Journal ArticleJAMA Neurol · January 1, 2023
IMPORTANCE: The Stroke of Known Cause and Underlying Atrial Fibrillation (STROKE AF) trial found that approximately 1 in 8 patients with recent ischemic stroke attributed to large- or small-vessel disease had poststroke atrial fibrillation (AF) detected by ...
Full textLink to itemCite
Journal ArticleJ Electrocardiol · 2023
BACKGROUND: Chronic right ventricular (RV) pacing can induce left ventricular (LV) dyssynchrony and cause pacemaker induced cardiomyopathy (PiCM). Identifying which patients are at risk for PiCM is limited. METHODS: Patients receiving RV-only permanent pac ...
Full textLink to itemCite
Journal ArticleHeart Rhythm O2 · January 2023
BACKGROUND: High-power, short-duration (HPSD) radiofrequency ablation (RFA) may reduce ablation time. Concerns that catheter-mounted thermocouples (TCs) can underestimate tissue temperature, resulting in elevated risk of steam pop formation, potentially li ...
Full textLink to itemCite
Journal ArticleClinicoecon Outcomes Res · 2023
BACKGROUND: Atrial fibrillation (AF) is associated with considerable morbidity and mortality. Timely management and treatment is critical in alleviating AF disease burden. Variation in treatment by race and ethnic and sex could lead to inequities in health ...
Full textLink to itemCite
Journal ArticleJ Med Econ · 2023
BACKGROUND: Postoperative atrial fibrillation (POAF) is one of the most common complications following cardiac surgery. POAF is associated with increased hospitalization costs, but its long-term economic burden is not well defined. OBJECTIVE: To assess 30- ...
Full textLink to itemCite
Journal ArticlePLoS One · 2023
Central retinal artery occlusion (CRAO; retinal stroke or eye stroke) is an under-recognized, disabling form of acute ischemic stroke which causes severe visual loss in one eye. The classical risk factor for CRAO is ipsilateral carotid stenosis; however, n ...
Full textLink to itemCite
Journal ArticleJournal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing · December 2022
PurposeMost centers performing catheter ablation (CA) of atrial fibrillation (AF) admit the patients for an overnight hospital stay to monitor for post-procedure complications, but the clinical benefits of this overnight hospital admission policy ...
Full textCite
Journal ArticleHeart Rhythm O2 · December 2022
BACKGROUND: Pulmonary vein (PV) isolation using radiofrequency ablation (RFA) to treat atrial fibrillation (AF) requires delivery of contiguous transmural lesions at the PV antra while avoiding injury to the esophagus. Continuous 2-dimensional phased-array ...
Full textLink to itemCite
Journal ArticleJAMA Cardiol · December 1, 2022
IMPORTANCE: Oral anticoagulation (OAC) is underprescribed in underrepresented racial and ethnic group individuals with atrial fibrillation (AF). Little is known of how differential OAC prescribing relates to inequities in AF outcomes. OBJECTIVE: To compare ...
Full textLink to itemCite
Journal ArticleCirc Arrhythm Electrophysiol · December 2022
Despite the global COVID-19 pandemic, during the past 2 years, there have been numerous advances in our understanding of arrhythmia mechanisms and diagnosis and in new therapies. We increased our understanding of risk factors and mechanisms of atrial arrhy ...
Full textLink to itemCite
Journal ArticleHeart Rhythm O2 · December 2022
BACKGROUND: Oral anticoagulation (OAC) reduces the risk of thromboembolic events in patients with atrial fibrillation (AF); however, thromboembolism (TE) still can occur despite OAC. Factors associated with residual risk for stroke, systemic embolism, or t ...
Full textLink to itemCite
Journal ArticleJACC Clin Electrophysiol · December 2022
BACKGROUND: Peak-to-peak bipolar voltage varies with electrode orientation, fractionation, and collision events. Novel, omnipolar mapping is less dependent on electrode orientation but has limited data in humans. OBJECTIVES: This study sought to compare bi ...
Full textLink to itemCite
Journal ArticleCirc Arrhythm Electrophysiol · November 2022
BACKGROUND: Difficulty of lead extraction does not track well with procedural complications, but several small retrospective studies have lead fibrosis on computed tomography as an important indicator of difficult lead extraction. The purpose of the presen ...
Full textLink to itemCite
Journal ArticleCirculation. Genomic and precision medicine · October 2022
BackgroundInherited primary arrhythmia syndromes and arrhythmogenic cardiomyopathies can lead to sudden cardiac arrest in otherwise healthy individuals. The burden and expression of these diseases in a real-world, well-phenotyped cardiovascular po ...
Full textCite
Journal ArticleAnn Intern Med · September 2022
BACKGROUND: Left atrial appendage occlusion (LAAO) is a potential alternative to oral anticoagulants in selected patients with atrial fibrillation (AF). Compared with anticoagulants, LAAO decreases major bleeding risk, but there is uncertainty regarding th ...
Full textOpen AccessLink to itemCite
Journal ArticleCirculation · August 16, 2022
BACKGROUND: In the CABANA trial (Catheter Ablation vs Antiarrhythmic Drug Therapy for Atrial Fibrillation), catheter ablation did not significantly reduce the primary end point of death, disabling stroke, serious bleeding, or cardiac arrest compared with d ...
Full textLink to itemCite
Journal ArticleHeart Rhythm · August 2022
BACKGROUND: The etiology of atrial fibrillation (AF) is multifactorial and incompletely understood. OBJECTIVE: The purpose of this study was to evaluate the association between coronary artery disease (CAD) affecting atrial tissue and AF. METHODS: Patients ...
Full textLink to itemCite
Journal ArticleEuropace · July 21, 2022
AIMS: There is limited information on what clinical factors are associated with the development of pericardial effusion after leadless pacemaker implantation. We sought to determine predictors of and to develop a risk score for pericardial effusion in pati ...
Full textLink to itemCite
Journal ArticleHeart Rhythm · July 2022
BACKGROUND: Despite multiple trials comparing rate with rhythm control, there is no consensus on the optimal management of first-detected atrial fibrillation (AF). OBJECTIVE: We analyzed current patterns of care for first-detected AF in the nationwide Get ...
Full textLink to itemCite
Journal ArticleEur J Heart Fail · June 2022
AIMS: Limited therapeutic options are available for the management of atrial fibrillation/flutter (AF/AFL) with concomitant heart failure (HF) with preserved (HFpEF) and mildly reduced ejection fraction (HFmrEF). Dronedarone reduces the risk of cardiovascu ...
Full textLink to itemCite
Journal ArticleHeart Rhythm · June 2022
BACKGROUND: An integrated, coordinated, and patient-centered approach to atrial fibrillation (AF) care delivery may improve outcomes and reduce cost. OBJECTIVE: The purpose of this study was to gain a better understanding from key stakeholder groups on cur ...
Full textLink to itemCite
Journal ArticleLancet · April 9, 2022
BACKGROUND: Direct-acting oral anticoagulant use for stroke prevention in atrial fibrillation is limited by bleeding concerns. Asundexian, a novel, oral small molecule activated coagulation factor XIa (FXIa) inhibitor, might reduce thrombosis with minimal ...
Full textLink to itemCite
Journal ArticleCirculation · March 22, 2022
BACKGROUND: We aimed to assess the prevalence of ischemic brain lesions detected by magnetic resonance imaging and their association with cognitive function 3 months after first-time ablation using continuous oral anticoagulation in patients with paroxysma ...
Full textLink to itemCite
Journal ArticleEur Heart J · March 21, 2022
AIMS: Clinical trials have demonstrated the safety and efficacy of the Micra leadless VVI pacemaker; however, longer-term outcomes in a large, real-world population with a contemporaneous comparison to transvenous VVI pacemakers have not been examined. We ...
Full textLink to itemCite
Journal ArticleJ Am Heart Assoc · March 15, 2022
Background Guideline recommendations are the accepted reference for selection of therapies for rhythm control of atrial fibrillation (AF). This study was designed to understand physicians' treatment practices and adherence to guidelines. Methods and Result ...
Full textLink to itemCite
Journal ArticleEur Heart J Qual Care Clin Outcomes · March 2, 2022
AIMS: To determine whether the Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF) integrated risk tool predicts mortality, non-haemorrhagic stroke/systemic embolism, and major bleeding for up to 2 years after new-onset AF and to a ...
Full textLink to itemCite
Journal ArticleAm Heart J · March 2022
BACKGROUND: Post-operative AF (POAF) is the most common complication following cardiac surgery, occurring in 30% to 60% of patients undergoing bypass and/or valve surgery. POAF is associated with longer intensive care unit/hospital stays, increased healthc ...
Full textLink to itemCite
Journal ArticleAm Heart J · March 2022
BACKGROUND: The Get With The Guidelines - Atrial Fibrillation (GWTG-AFIB) Registry uses achievement and quality measures to improve the care of patients with atrial fibrillation (AF). We sought to evaluate overall and site-level variation in attainment of ...
Full textLink to itemCite
Journal ArticleJ Cardiovasc Electrophysiol · March 2022
BACKGROUND: Cardiac implanted electronic device (CIED) pocket and systemic infection remain common complications with traditional CIEDs and are associated with high morbidity and mortality. Leadless pacemakers may be an attractive pacing alternative for ma ...
Full textLink to itemCite
Journal ArticleJ Acquir Immune Defic Syndr · March 1, 2022
BACKGROUND: People with HIV (PWH) are at increased risk of cardiovasvular disease (CVD) and sudden cardiac death. Previous work has suggested an association between HIV infection and electrocardiographic (ECG) abnormalities. There are limited data on the b ...
Full textLink to itemCite
Journal ArticleJ Am Heart Assoc · February 15, 2022
Background Currently, little is known regarding seasonal variation for atrial fibrillation (AF) in the United States and whether quality of care for AF varies between seasons. Methods and Results The GWTG-AFib (Get With The Guidelines-AFib) registry was in ...
Full textLink to itemCite
Journal ArticleHeart Rhythm · February 2022
BACKGROUND: Early results from the Micra investigational trial and Micra Post-Approval Registry (PAR) demonstrated excellent safety and device performance; however, outcomes based on anticoagulation (AC) status at implant have not been evaluated. OBJECTIVE ...
Full textLink to itemCite
Journal ArticleAm Heart J · February 2022
BACKGROUND: As the prevalence of atrial fibrillation (AF) increases, a greater understanding of the costs associated with AF care is required. While individuals with greater arrhythmic burden may interact with the health system more frequently, the relatio ...
Full textLink to itemCite
Journal ArticleAm Heart J · February 2022
BACKGROUND: Burden of atrial fibrillation (AF), as a continuous measure, is an emerging alternative classification often assumed to increase linearly with progression of disease. Yet there are no descriptions of AF burden distributions across populations. ...
Full textLink to itemCite
Journal ArticleJ Am Heart Assoc · February 2022
Background One-quarter of all strokes are subsequent events. It is not known whether higher levels of blood glucose are associated with an increased risk of subsequent stroke after high-risk transient ischemic attack or minor ischemic stroke. Methods and R ...
Full textLink to itemCite
Journal ArticleJ Am Heart Assoc · February 2022
Background Atrial tachyarrhythmias are common after atrial fibrillation ablation, so adjunctive antiarrhythmic drug therapy is often used. Data on the effectiveness and safety of dronedarone and sotalol after AF ablation are limited. Here, we compared heal ...
Full textLink to itemCite
Journal ArticleCirc Arrhythm Electrophysiol · February 2022
BACKGROUND: Whether the amount of atrial fibrillation (AF) patients experience conveys important prognostic information beyond that provided by the diagnosis of AF is uncertain. The study objective was to assess the dose-response relationship between devic ...
Full textLink to itemCite
Journal ArticleHeart Rhythm O2 · February 2022
BACKGROUND: Procedural and clinical outcomes of patients undergoing extraction or removal of azygous coils are not well characterized. OBJECTIVE: Evaluate outcomes in patients who undergo device extraction with an azygous coil in situ. METHODS: Patients un ...
Full textLink to itemCite
Journal ArticleHeart Rhythm O2 · February 2022
BACKGROUND: Multiple class I and class IIa recommendations exist related to surgical ablation (SA) of atrial fibrillation (AF) in patients undergoing cardiac surgery. OBJECTIVE: Examine temporal trends and predictors of SA for AF in a large US healthcare s ...
Full textLink to itemCite
Journal ArticleHeart Rhythm O2 · February 2022
BACKGROUND: Wait times for catheter ablation in patients with symptomatic atrial fibrillation (AF) may influence clinical outcomes. OBJECTIVE: This study examined the relationship between the duration from AF diagnosis to ablation, or diagnosis-to-ablation ...
Full textOpen AccessLink to itemCite
Journal ArticleHeart Rhythm O2 · February 2022
BACKGROUND: Heart failure (HF) patients with atrial fibrillation (AF) often have conduction system disorders, which may be worsened by β-blocker therapy. OBJECTIVE: In a post hoc analysis we examined the prevalence of bradycardia and its association with a ...
Full textLink to itemCite
Journal ArticleCirculation · January 25, 2022
BACKGROUND: Direct oral anticoagulants (DOACs) are preferred over warfarin for stroke prevention in atrial fibrillation. Meta-analyses using individual patient data offer substantial advantages over study-level data. METHODS: We used individual patient dat ...
Full textLink to itemCite
Journal ArticleBMJ Open · January 7, 2022
OBJECTIVE: In patients with newly diagnosed atrial fibrillation (AF), do baseline risk factors and stroke prevention strategies account for the geographically diverse outcomes. DESIGN: Global Anticoagulant Registry in the FIELD-Atrial Fibrillation is a pro ...
Full textLink to itemCite
Journal ArticleJ Card Fail · January 2022
BACKGROUND: Atrial fibrillation (AF) frequently complicates heart failure (HF), and each is associated with lower overall health-related quality of life. We aimed to quantify the incremental burden of AF on the health-related quality of life of patients wi ...
Full textLink to itemCite
Journal ArticleAm Heart J · January 2022
Randomized controlled trials (RCTs) are considered the gold standard for estimating the effectiveness of a treatment. However, in many instances they are impractical to conduct because of time limitations, cost restrictions, or ethical reasons. As a conseq ...
Full textLink to itemCite
Journal ArticleBMJ Open · December 30, 2021
INTRODUCTION: Personal digital devices that provide health information, such as the Apple Watch, have developed an increasing array of cardiopulmonary tracking features which have received regulatory clearance and are directly marketed to consumers. Despit ...
Full textLink to itemCite
Journal ArticleAm Heart J · December 2021
BACKGROUND: Chronic Kidney Disease (CKD) and end-stage renal disease (ESRD) are associated with poor outcomes in patients with cardiovascular disease. There is a paucity of contemporary data on in-hospital outcomes and care patterns of atrial fibrillation ...
Full textLink to itemCite
Journal ArticleCirc Cardiovasc Interv · December 2021
BACKGROUND: Older adults with atrial fibrillation (AF) are often treated with the shortest possible duration of antiplatelet/anticoagulant therapy after myocardial infarction (MI) or percutaneous coronary intervention (PCI) due to concern for bleeding. How ...
Full textLink to itemCite
Journal ArticleHeart Rhythm O2 · December 2021
BACKGROUND: Although lesion transmurality is required for durable pulmonary vein isolation, excess ablation is associated with increased risk of complications. OBJECTIVE: We sought to understand the impact of interrupted radiofrequency (RF) delivery condit ...
Full textLink to itemCite
Journal ArticleEuropean Heart Journal - Digital Health · December 1, 2021
In the originally published version of this manuscript, disclosure of several authors' handling editor statuses was omitted from the supplementary material in error. This error has been corrected online. ...
Full textCite
Journal ArticleCirc Arrhythm Electrophysiol · November 2021
BACKGROUND: When presenting for atrial fibrillation (AF) ablation, women, compared with men, tend to have more nonpulmonary vein triggers and advanced atrial disease. Whether this informs differences in AF ablation strategy is not well described. We aimed ...
Full textLink to itemCite
Journal ArticleJ Am Heart Assoc · October 5, 2021
Background In event-driven clinical trials, study termination is based on accrual of a target number of primary efficacy events. For noninferiority trials in which superiority is conditionally examined, the ideal cohort in which to track event accrual is u ...
Full textLink to itemCite
Journal ArticleJAMA Cardiol · October 1, 2021
IMPORTANCE: The safety and efficacy of leadless VVI pacemakers have been demonstrated in multiple clinical trials, but the comparative performance of the device in a large, real-world population has not been examined. OBJECTIVE: To compare patient characte ...
Full textLink to itemCite
Journal ArticleHeart Rhythm O2 · October 2021
BACKGROUND: Atrioventricular (AV)-synchronous single-chamber leadless pacing using a mechanical atrial sensing algorithm produced high AV synchrony in clinical trials, but clinical practice experience with these devices has not yet been described. OBJECTIV ...
Full textOpen AccessLink to itemCite
Journal ArticleAm J Cardiovasc Drugs · September 2021
INTRODUCTION: Direct oral anticoagulants (DOACs) have partial renal clearance and generally require dosage adjustments based on renal function. While current US and European guidance recommends dose adjustments in patients with moderate chronic kidney dise ...
Full textLink to itemCite
Journal ArticleJ Cardiovasc Electrophysiol · September 2021
The left atrial posterior wall has many embryologic, anatomic, and electrophysiologic characteristics, that are important for the initiation and maintenance of persistent atrial fibrillation. The left atrial posterior wall is a potential target for ablatio ...
Full textLink to itemCite
Journal ArticleEuropace · August 6, 2021
Catheter ablation is superior to antiarrhythmic therapy for the reduction of symptomatic atrial fibrillation (AF), recurrence, and burden. The possibility of a true 'rhythm' control strategy with catheter ablation has re-opened the debate on rate vs. rhyth ...
Full textLink to itemCite
Journal ArticleHeart Rhythm · August 2021
BACKGROUND: Ventricular arrhythmias (VAs) and electrical storm (ES) are recognized complications following left ventricular assist device (LVAD) implantation; however, their association with long term-outcomes remains poorly understood. OBJECTIVE: The purp ...
Full textLink to itemCite
Journal ArticleAm Heart J · July 2021
BACKGROUND: Improving adherence to direct oral anticoagulants (DOAC) is challenging, and simple text messaging reminders have not been effective. METHODS: SmartADHERE was a randomized trial that tested a personalized digital and human direct oral anticoagu ...
Full textLink to itemCite
Journal ArticleJ Cardiovasc Electrophysiol · July 2021
INTRODUCTION: MARVEL 2 assessed the efficacy of mechanical atrial sensing by a ventricular leadless pacemaker, enabling a VDD pacing mode. The behavior of the enhanced MARVEL 2 algorithm during variable atrio-ventricular conduction (AVC) and/or arrhythmias ...
Full textLink to itemCite
Journal ArticleAm Heart J · June 2021
BACKGROUND: ROCKET AF demonstrated the efficacy and safety of rivaroxaban compared with warfarin for the prevention of stroke and systemic embolism (SE) in patients with atrial fibrillation (AF). We examined baseline characteristics and outcomes in patient ...
Full textLink to itemCite
Journal ArticleJAMA · June 2021
ImportancePatients with ischemic stroke attributed to large- or small-vessel disease are not considered at high risk for atrial fibrillation (AF), and the AF incidence rate in this population is unknown.ObjectivesTo determine whether long ...
Full textCite
Journal ArticleHeart Rhythm O2 · June 2021
BACKGROUND: Insulin use may be a better predictor of stroke risk and morbidity and mortality than diabetes in patients with atrial fibrillation (AF). OBJECTIVES: Determine if the increased risk of stroke observed in patients with AF and diabetes is restric ...
Full textLink to itemCite
Journal ArticleHeart Rhythm · May 2021
BACKGROUND: Atrial fibrillation (AF) and heart failure (HF) often accompany one another, and each is independently associated with poor outcomes. However, the association between AF burden and outcomes is poorly understood. OBJECTIVE: The purpose of this s ...
Full textLink to itemCite
Journal ArticleCirculation · April 6, 2021
BACKGROUND: In patients with heart failure and atrial fibrillation (AF), several clinical trials have reported improved outcomes, including freedom from AF recurrence, quality of life, and survival, with catheter ablation. This article describes the treatm ...
Full textOpen AccessLink to itemCite
Journal ArticleHeart · April 2021
BACKGROUND: Cardioversion is common among patients with atrial fibrillation (AF). We hypothesised that novel oral anticoagulants (NOAC) used in clinical practice resulted in similar rates of stroke compared with vitamin K antagonists (VKA) for cardioversio ...
Full textLink to itemCite
Journal ArticleJACC Clin Electrophysiol · April 2021
OBJECTIVES: This study sought to formulate a predictive model for describing the long-term electrical performance of Micra (Medtronic, Mounds View, Minnesota). BACKGROUND: The Micra leadless pacemaker is an alternative ventricular pacing option that avoids ...
Full textLink to itemCite
Journal ArticleCirc Cardiovasc Interv · April 2021
BACKGROUND: Optimal antithrombotic management of patients with preexisting atrial fibrillation undergoing transcatheter aortic valve replacement is challenging given the need to balance the risk of bleeding and thromboembolism. We aimed to examine variatio ...
Full textLink to itemCite
Journal ArticleJournal of Arrhythmia · April 1, 2021
This collaborative statement from the International Society for Holter and Noninvasive Electrocardiology/Heart Rhythm Society/European Heart Rhythm Association/Asia Pacific Heart Rhythm Society describes the current status of mobile health (“mHealth”) tech ...
Full textCite
Journal ArticleAm Heart J · March 2021
BACKGROUND: Non-vitamin K antagonist oral anticoagulants (NOACs) are the preferred class of medications for prevention of stroke and systemic embolism in patients with atrial fibrillation unless contraindications exist. Five large, international, randomize ...
Full textLink to itemCite
Journal ArticleJ Cardiovasc Electrophysiol · March 2021
BACKGROUND: The feasibility and outcomes of concomitant atrioventricular node ablation (AVNA) and leadless pacemaker implant are not well studied. We report outcomes in patients undergoing Micra implant with concomitant AVNA. METHODS: Patients undergoing A ...
Full textLink to itemCite
Journal ArticleAnn Noninvasive Electrocardiol · March 2021
This collaborative statement from the International Society for Holter and Noninvasive Electrocardiology/ Heart Rhythm Society/ European Heart Rhythm Association/ Asia Pacific Heart Rhythm Society describes the current status of mobile health ("mHealth") t ...
Full textLink to itemCite
Journal ArticleEuropean Heart Journal - Digital Health · March 1, 2021
This collaborative statement from the International Society for Holter and Noninvasive Electrocardiology / Heart Rhythm Society / European Heart Rhythm Association / Asia Pacific Heart Rhythm Society describes the current status of mobile health ("mHealth" ...
Full textCite
Journal ArticleJ Cardiovasc Electrophysiol · February 2021
INTRODUCTION: Cryoballoon ablation (CBA) is an alternative to radiofrequency ablation (RFA) for ablation of atrial fibrillation (AF) and real-world comparisons of this strategy are lacking. As such, we sought to compare patient and periprocedural character ...
Full textLink to itemCite
Journal ArticleCirc Arrhythm Electrophysiol · February 2021
BACKGROUND: Antiarrhythmic drug (AAD) therapy for atrial fibrillation (AF) can be associated with both proarrhythmic and noncardiovascular toxicities. Practice guidelines recommend tailored AAD therapy for AF based on patient-specific characteristics, such ...
Full textLink to itemCite
Journal ArticleJAMA Netw Open · February 1, 2021
IMPORTANCE: Although the use of factor Xa (FXa) inhibitors has increased substantially over the past decade, there are limited data on characteristics and outcomes of FXa inhibitor-associated intracerebral hemorrhage (ICH). OBJECTIVE: To investigate the as ...
Full textLink to itemCite
Journal ArticleCirc Arrhythm Electrophysiol · February 2021
This collaborative statement from the International Society for Holter and Noninvasive Electrocardiology/Heart Rhythm Society/European Heart Rhythm Association/Asia-Pacific Heart Rhythm Society describes the current status of mobile health technologies in ...
Full textLink to itemCite
Journal ArticleHeart rhythm O2 · February 2021
BackgroundAblation reduces atrial fibrillation (AF) burden and improves health-related quality of life. The relationship between ablation, healthcare utilization, and AF type (paroxysmal AF [PAF] vs persistent AF [PsAF]) remains unclear.Object ...
Full textCite
Journal ArticleCardiovasc Digit Health J · February 2021
This collaborative statement from the International Society for Holter and Noninvasive Electrocardiology/Heart Rhythm Society/European Heart Rhythm Association/Asia Pacific Heart Rhythm Society describes the current status of mobile health ("mHealth") tech ...
Full textLink to itemCite
Journal ArticleCirculation · January 26, 2021
Clinically recognized atrial fibrillation (AF) is associated with higher risk of complications, including ischemic stroke, cognitive decline, heart failure, myocardial infarction, and death. It is increasingly recognized that AF frequently is undetected un ...
Full textLink to itemCite
Journal ArticleAm Heart J · January 2021
BACKGROUND: The coronavirus disease 2019 (COVID-19) pandemic brought about abrupt changes in the way health care is delivered, and the impact of transitioning outpatient clinic visits to telehealth visits on processes of care and outcomes is unclear. METHO ...
Full textLink to itemCite
Journal ArticleJ Electrocardiol · 2021
OBJECTIVE: We designed an automatic, computationally efficient, and interpretable algorithm for detecting ventricular ectopic beats in long-term, single-lead electrocardiogram recordings. METHODS: We built five simple, interpretable, and computationally ef ...
Full textLink to itemCite
Journal ArticleRussian Journal of Cardiology · January 1, 2021
This collaborative statement from the International Society for Holter and Noninvasive Electrocardiology/Heart Rhythm Society/European Heart Rhythm Association/Asia Pacific Heart Rhythm Society describes the current status of mobile health (“mHealth”) tech ...
Full textCite
Journal ArticleClin Nutr · December 2020
BACKGROUND & AIMS: Primary prevention of atrial fibrillation (AF) through behavioural and dietary modification is a critically important and unmet need. Flavonoids are bioactive dietary compounds with promising cardiovascular health benefits. Our aim was t ...
Full textLink to itemCite
Journal ArticleJ Cardiovasc Transl Res · December 2020
COVID-19 is a syndrome that includes more than just isolated respiratory disease, as severe acute respiratory syndrome-coronavirus 2 (SARS-CoV2) also interacts with the cardiovascular, nervous, renal, and immune system at multiple levels, increasing morbid ...
Full textOpen AccessLink to itemCite
Journal ArticleHeart Rhythm · December 2020
BACKGROUND: The MARVEL (Micra Atrial TRacking Using a Ventricular AccELerometer) 2 study assessed the efficacy of atrioventricular (AV) synchronous pacing with a Micra leadless pacemaker. Average atrioventricular synchrony (AVS) was 89.2%. Previously, low ...
Full textLink to itemCite
Journal ArticleHeart Rhythm · December 2020
BACKGROUND: The Micra transcatheter pacemaker is a safe and effective alternative to transvenous permanent pacemakers (TV-PPMs). However, the safety profile and mortality outcomes of Micra implantation in patients deemed poor candidates for TV-PPM are inco ...
Full textLink to itemCite
Journal ArticleEur J Heart Fail · December 2020
The Heart Failure Academic Research Consortium is a partnership between the Heart Failure Collaboratory (HFC) and Academic Research Consortium (ARC), comprised of leading heart failure (HF) academic research investigators, patients, United States (US) Food ...
Full textLink to itemCite
Journal ArticleJ Cardiovasc Electrophysiol · December 2020
BACKGROUND: Catheter ablation is an effective treatment for patients with atrial fibrillation (AF) and heart failure (HF). However, little is known about how healthcare utilization and cost change after ablation in this population. We sought to determine h ...
Full textLink to itemCite
Journal ArticleHeart · December 2020
OBJECTIVE: To investigate changes in quality of life (QoL), cognition and functional status according to arrhythmia recurrence after atrial fibrillation (AF) ablation. METHODS: We compared QoL, cognition and functional status in patients with recurrent atr ...
Full textLink to itemCite
Journal ArticlePacing Clin Electrophysiol · December 2020
BACKGROUND: Leadless pacemakers (LPs) provide ventricular pacing without the risks associated with transvenous leads and device pockets. LPs are appealing for patients who need pacing, but do not need defibrillator or cardiac resynchronization therapy. Mos ...
Full textOpen AccessLink to itemCite
Journal ArticleJ Cardiovasc Electrophysiol · December 2020
BACKGROUND: Atrial fibrillation (AF) significantly reduces health-related quality of life (HRQoL), previously measured in clinical trials using patient-reported outcomes (PROs). We examined AF PROs in clinical practice and their association with subsequent ...
Full textLink to itemCite
Journal ArticleJ Am Heart Assoc · December 2020
Background Knowledge is scarce regarding how multimorbidity is associated with therapeutic decisions regarding oral anticoagulants (OACs) in patients with atrial fibrillation. Methods and Results We conducted a cross-sectional study of hospitalized patient ...
Full textOpen AccessLink to itemCite
Journal ArticleJACC Heart Fail · December 2020
The Heart Failure Academic Research Consortium is a partnership between the Heart Failure Collaboratory (HFC) and Academic Research Consortium (ARC), comprised of leading heart failure (HF) academic research investigators, patients, United States (US) Food ...
Full textLink to itemCite
Journal ArticleCirc Cardiovasc Qual Outcomes · December 2020
BACKGROUND: Randomized clinical trials have demonstrated that catheter ablation for atrial fibrillation in patients with heart failure with reduced ejection fraction may improve survival and other cardiovascular outcomes. METHODS: We constructed a decision ...
Full textLink to itemCite
ConferenceCirculation · November 17, 2020
Background:
Atrial Fibrillation (AF) is common in patients with Type 2 diabetes mellitus and it is associated with adverse outcomes. The impact of SGLT-2 inhibitors on incident AF and cardiovascular o ...
Full textCite
ConferenceEuropace · November 1, 2020
AIMS: Prediction models for outcomes in atrial fibrillation (AF) are used to guide treatment. While regression models have been the analytic standard for prediction modelling, machine learning (ML) has been promoted as a potentially superior methodology. W ...
Full textLink to itemCite
Journal ArticleCirc Arrhythm Electrophysiol · November 2020
BACKGROUND: Social media has become a major source of communication in medicine. We aimed to understand the relationship between physicians' social media influence and their scholarly and clinical activity. METHODS: We identified attending US electrophysio ...
Full textLink to itemCite
Journal ArticleCurr Hypertens Rep · October 23, 2020
PURPOSE OF REVIEW: To highlight the indications, procedural considerations, and data supporting the use of stellate ganglion blockade (SGB) for management of refractory ventricular arrhythmias. RECENT FINDINGS: In patients with refractory ventricular arrhy ...
Full textOpen AccessLink to itemCite
Journal ArticleJ Nucl Cardiol · October 2020
BACKGROUND: Prevalence and prognostic value of diastolic and systolic dyssynchrony in patients with coronary artery disease (CAD) + heart failure (HF) or CAD alone are not well understood. METHODS: We included patients with gated single-photon emission com ...
Full textLink to itemCite
Journal ArticleEur Heart J Qual Care Clin Outcomes · October 1, 2020
AIMS: To determine the extent of shared decision-making (SDM), during selection of oral anticoagulant (OAC) and rhythm control treatments, in patients with newly diagnosed atrial fibrillation (AF). METHODS AND RESULTS: We evaluated survey data from 1006 pa ...
Full textLink to itemCite
Journal ArticleAm J Cardiol · October 1, 2020
The aim of this study was to quantify time in therapeutic range (TTR) before and after a temporary interruption of warfarin due to an intervention in the Outcomes Registry for Better Informed Treatment of atrial fibrillation (AF). AF patients on warfarin w ...
Full textLink to itemCite
Journal ArticleHeart Rhythm · September 2020
BACKGROUND: There are limited data on the performance of the subcutaneous implantable cardioverter-defibrillator (S-ICD) in patients with a left ventricular assist device (LVAD). OBJECTIVE: The purpose of this study was to describe the clinical course and ...
Full textLink to itemCite
Journal ArticlePacing Clin Electrophysiol · September 2020
BACKGROUND: Cardiac amyloidosis is a progressive infiltrative disease involving deposition of amyloid fibrils in the myocardium and cardiac conduction system that frequently manifests with heart failure (HF) and arrhythmias, most frequently atrial fibrilla ...
Full textLink to itemCite
Journal ArticleCirc Arrhythm Electrophysiol · September 2020
BACKGROUND: Catheter ablation is an increasingly used treatment for symptomatic atrial fibrillation (AF). However, there are limited prospective, nationwide data on patient selection and procedural characteristics. This study describes patient characterist ...
Full textLink to itemCite
Journal ArticleEuropace · September 1, 2020
AIMS: Freedom from atrial fibrillation (AF) at 1 year can be achieved in 50-70% of patients undergoing catheter ablation. Recurrent AF early after ablation most commonly terminates spontaneously without further interventional treatment but is associated wi ...
Full textLink to itemCite
Journal ArticleJACC Clin Electrophysiol · September 2020
OBJECTIVES: This study sought to determine the indications, characteristics, and outcomes of cardiovascular implantable electronic device (CIED) surgery in patients with LVAD. BACKGROUND: Many patients with a left ventricular assist device (LVAD) will requ ...
Full textLink to itemCite
Journal ArticleJ Am Heart Assoc · August 18, 2020
Background Left ventricular assist devices (LVADs) generate electromagnetic interference that causes high-frequency noise artifacts on 12-lead ECGs. We describe the causes of this interference and potential solutions to aid ECG interpretation in patients w ...
Full textLink to itemCite
Journal ArticleHeart Rhythm · August 2020
BACKGROUND: During catheter ablation, delivery of radiofrequency (RF) energy to a target site is sometimes interrupted by catheter instability and clinical factors. The impact of interruption of RF delivery on lesion characteristics has not been characteri ...
Full textLink to itemCite
Journal ArticleHeart Rhythm O2 · August 2020
BACKGROUND: Diabetes mellitus (DM) is an independent risk factor for atrial fibrillation (AF). Few studies have compared clinical outcomes after catheter ablation between patients with and those without DM. OBJECTIVE: The purpose of this study was to compa ...
Full textOpen AccessLink to itemCite
Journal ArticleAm Heart J · August 2020
UNLABELLED: While oral anticoagulation is a cornerstone of stroke prevention therapy in atrial fibrillation (AF), few studies have evaluated comparative discontinuation rates in clinical practice. The objective of this study is to evaluate discontinuation ...
Full textLink to itemCite
Journal ArticleCirc Arrhythm Electrophysiol · August 2020
Artificial intelligence (AI) and machine learning (ML) in medicine are currently areas of intense exploration, showing potential to automate human tasks and even perform tasks beyond human capabilities. Literacy and understanding of AI/ML methods are becom ...
Full textLink to itemCite
Journal ArticleHeart Rhythm O2 · August 2020
BACKGROUND: Although there are considerable data on the safety of cryoablation, data on the rare but severe complication of atrioesophageal fistula (AEF) following cryoballoon ablation are limited. OBJECTIVE: To report the global, user-reported incidence o ...
Full textLink to itemCite
Journal ArticleJ Cardiovasc Electrophysiol · July 2020
Due to the growing number of patients treated with cardiac implantable electronic devices (CIEDs) there is an increased need for lead management, evaluation, and extraction. While CIED lead extraction has many indications, a consistent approach to preproce ...
Full textLink to itemCite
Journal ArticleJ Cardiovasc Electrophysiol · July 2020
Catheter ablation is commonly used for treatment of persistent atrial fibrillation (AF). Pulmonary vein isolation (PVI) is still the cornerstone for the procedure, however, outcomes are consistently lower compared to paroxysmal AF. It is hypothesized that ...
Full textLink to itemCite
Journal ArticleEuropace · July 1, 2020
AIMS: Study sex-differences in efficacy and safety of atrial fibrillation (AF) ablation. METHODS AND RESULTS: We assessed first AF ablation outcomes on continuous anticoagulation in 633 patients [209 (33%) women and 424 (67%) men] in a pre-specified subgro ...
Full textLink to itemCite
Journal ArticleHeart Rhythm · July 2020
BACKGROUND: In the Catheter Ablation for Atrial Fibrillation with Heart Failure (CASTLE-AF) trial, catheter ablation reduced the risk of death and heart failure (HF) hospitalization in patients with atrial fibrillation and HF by 40%. OBJECTIVES: The study ...
Full textLink to itemCite
Journal ArticleAm Heart J · July 2020
The infection caused by severe acute respiratory syndrome coronavirus-2, or COVID-19, can result in myocardial injury, heart failure, and arrhythmias. In addition to the viral infection itself, investigational therapies for the infection can interact with ...
Full textLink to itemCite
Journal ArticleJ Cardiovasc Electrophysiol · June 2020
INTRODUCTION: Lead dysfunction can lead to serious consequences including failure to treat ventricular tachycardia or fibrillation (VT/VF). The incidence and mechanisms of lead dysfunction following left ventricular assist device (LVAD) implantation are no ...
Full textLink to itemCite
Journal ArticleJACC. Clinical electrophysiology · June 2020
ObjectivesThis study identified factors associated with risk for cardiac perforation in the setting of atrial fibrillation (AF) ablation in contemporary clinical practice.BackgroundCardiac perforation is an uncommon but potentially fatal ...
Full textCite
Journal ArticleJACC Clin Electrophysiol · June 2020
OBJECTIVES: The goal of this study was to assess the utility of transvenous lead extraction for cardiovascular implantable electronic device (CIED) infection in patients with a left ventricular assist device (LVAD). BACKGROUND: The use of transvenous lead ...
Full textLink to itemCite
Journal ArticleAm Heart J · May 2020
BACKGROUND: Obstructive sleep apnea (OSA) is a known risk factor for atrial fibrillation (AF). However, it remains unclear whether OSA is independently associated with worse cardiovascular and neurological outcomes in patients with AF. METHODS: We used the ...
Full textLink to itemCite
Journal ArticleCirc Arrhythm Electrophysiol · May 2020
BACKGROUND: Atrial fibrillation (AF) adversely impacts health-related quality of life (hrQoL). While some patients demonstrate improvements in hrQoL, the factors associated with large improvements in hrQoL are not well described. METHODS: We assessed facto ...
Full textLink to itemCite
Journal ArticleJACC Clin Electrophysiol · May 2020
OBJECTIVES: This study sought to describe our institutional experience with establishing a neurocardiology service in an attempt to provide autonomic modulation as a treatment for ventricular arrhythmias (VAs). BACKGROUND: Treatment-refractory VAs are comm ...
Full textLink to itemCite
Journal ArticleEuropace · May 1, 2020
The field of observational studies or "real world studies" is in rapid development with many new techniques introduced and increased understanding of traditional methods. For this reason the current paper provides an overview of current methods with focus ...
Full textLink to itemCite
Journal ArticleCirc Cardiovasc Interv · May 2020
BACKGROUND: Patients with atrial fibrillation on oral anticoagulation (OAC) undergoing cardiac catheterization face risks for embolic and bleeding events, yet information on strategies to mitigate these risks in contemporary practice is lacking. METHODS: W ...
Full textLink to itemCite
Journal ArticleJ Interv Card Electrophysiol · April 2020
PURPOSE: Patients with atrial fibrillation (AF) undergoing cardiac surgery are at substantially increased risk for stroke. Increasing evidence has suggested that surgical left atrial appendage occlusion (S-LAAO) may have the potential to substantially miti ...
Full textLink to itemCite
Journal ArticleHeart Rhythm · April 2020
BACKGROUND: In observational studies, case reports, and animal studies, amiodarone has been associated with incident cancer. OBJECTIVE: The purpose of this study was to examine whether a dose-response relationship between amiodarone use and the risk of can ...
Full textLink to itemCite
Journal ArticleCirc Arrhythm Electrophysiol · April 2020
BACKGROUND: The optimal timing of catheter ablation for atrial fibrillation (AF) in reference to the time of diagnosis is unknown. We sought to assess the impact of the duration between first diagnosis of AF and ablation, or diagnosis-to-ablation time (DAT ...
Full textLink to itemCite
Journal ArticleJ Arrhythm · April 2020
BACKGROUND: Focal impulse and rotor modulation (FIRM) can cause slowing, organization, and occasionally termination of atrial fibrillation (AF), although results have been mixed. To further characterize changes in AF during rotor ablation, we quantified mo ...
Full textLink to itemCite
Journal ArticleJ Am Coll Cardiol · March 24, 2020
BACKGROUND: Atrial fibrillation (AF) is common in patients with end-stage renal disease (ESRD). The impact of oral anticoagulation (OAC) in ESRD patients is uncertain. OBJECTIVES: The purpose of this study was to describe patterns of OAC use in ESRD patien ...
Full textLink to itemCite
Journal ArticleAm J Cardiol · March 15, 2020
Randomized data suggest lenient rate control (resting heart rate <110 beats/min) is noninferior to strict rate control (resting heart rate <80 beats/min) in patients with atrial fibrillation (AF). However, the optimal rate control strategy in patients with ...
Full textLink to itemCite
Journal ArticleHeart Rhythm · March 2020
BACKGROUND: Reports on the subcutaneous implantable cardioverter-defibrillator (S-ICD) cumulatively demonstrate a low rate of complications, but clinical experience with this technology is limited compared with transvenous devices. OBJECTIVE: The purpose o ...
Full textLink to itemCite
Journal ArticleEuropace · March 1, 2020
AIMS: Incorporating patient-reported outcomes (PROs) into routine care of atrial fibrillation (AF) enables direct integration of symptoms, function, and health-related quality of life (HRQoL) into practice. We report our initial experience with a system-wi ...
Full textLink to itemCite
Journal ArticleHeart · March 2020
OBJECTIVE: Non-vitamin K oral anticoagulants (NOACs) require dose adjustment for renal function. We sought to investigate change in renal function over time in patients with atrial fibrillation (AF) and whether those on NOACs have appropriate dose adjustme ...
Full textLink to itemCite
Journal ArticleJ Cardiovasc Electrophysiol · March 2020
Cardiac implantable electronic devices (CIEDs) frequently need to be extracted due to infection, hardware failure, and other causes. The extraction of the CIED is typically performed using percutaneous methods. While these procedures are mostly performed w ...
Full textLink to itemCite
Journal ArticleCirculation · February 11, 2020
Catheter ablation has brought major advances in the management of patients with atrial fibrillation (AF). As evidenced by multiple randomized trials, AF catheter ablation can reduce the risk of recurrent AF and improve quality of life. In some studies, AF ...
Full textLink to itemCite
Journal ArticleAm Heart J · February 2020
BACKGROUND: Pulmonary wall isolation (PWI) is increasingly used as an adjunctive lesion set to compliment pulmonary vein isolation (PVI), especially in patients with persistent atrial fibrillation (AF). The objective was to compare outcomes of catheter abl ...
Full textLink to itemCite
Journal ArticleAm Heart J · February 2020
BACKGROUND: Amiodarone is the most effective antiarrhythmic drug (AAD) for atrial fibrillation (AF), but it has a high incidence of adverse effects. METHODS: Using the ORBIT AF registry, patients with AF on amiodarone at enrollment, prescribed amiodarone d ...
Full textLink to itemCite
Journal ArticleJ Arrhythm · February 2020
BACKGROUND: Catheter ablation is an important rhythm control therapy in patients with atrial fibrillation (AF) with concomitant heart failure (HF). The objective of this study was to assess the comparative efficacy of AF ablation patients with ischemic vs ...
Full textOpen AccessLink to itemCite
Journal ArticleHeart Rhythm · January 2020
BACKGROUND: Antitachycardia pacing (ATP) is routinely used to terminate ventricular tachyarrhythmias (VTs). However, little guidance exists on the most effective programming of ATP. OBJECTIVE: This study evaluated whether additional ATP sequences are more ...
Full textLink to itemCite
Journal ArticleAm Heart J · January 2020
BACKGROUND: Comorbidities are common in patients with atrial fibrillation (AF) and affect prognosis, yet are often undertreated. However, contemporary rates of use of guideline-directed therapies (GDT) for non-AF comorbidities and their association with ou ...
Full textLink to itemCite
Journal ArticleJACC Clin Electrophysiol · January 2020
OBJECTIVES: This study reports on the performance of a leadless ventricular pacemaker with automated, enhanced accelerometer-based algorithms that provide atrioventricular (AV) synchronous pacing. BACKGROUND: Despite many advantages, leadless pacemakers ar ...
Full textLink to itemCite
Journal ArticleBMJ Open · December 18, 2019
PURPOSE: Besides the high rates of morbidity and mortality, atrial fibrillation (AF) is also associated with impairment of quality-of-life (QOL). However, reports covering non-selected AF population within Asian countries remain scarce. The objective of th ...
Full textLink to itemCite
Journal ArticleJ Am Heart Assoc · December 17, 2019
Background Limited data exist to guide treatment for patients with heart failure with preserved ejection fraction and atrial fibrillation, including the important decision regarding rate versus rhythm control. Methods and Results We analyzed the Get With T ...
Full textLink to itemCite
Journal ArticleJ Clin Sleep Med · December 15, 2019
STUDY OBJECTIVES: Early evidence with transvenous phrenic nerve stimulation (PNS) demonstrates improved disease severity and quality of life (QOL) in patients with central sleep apnea (CSA). The goal of this analysis is to evaluate the complete prospective ...
Full textLink to itemCite
Journal ArticleCardiol Ther · December 2019
INTRODUCTION: Patient-reported outcomes (PROs) and satisfaction endpoints are increasingly important in clinical trials and may be associated with treatment adherence. In this post hoc substudy from ROCKET AF, we examined whether patient-reported satisfact ...
Full textLink to itemCite
Journal ArticleJ Cardiovasc Electrophysiol · December 2019
Atrial fibrillation (AF) is the most common clinically relevant arrhythmia and confers a fivefold increased risk for stroke. Cardioembolic stroke secondary to AF is a devastating event, but is largely preventable with appropriate oral anticoagulation (OAC) ...
Full textLink to itemCite
Journal ArticleCirc Arrhythm Electrophysiol · December 2019
BACKGROUND: Studies evaluating the effects of atrial fibrillation (AF) catheter ablation versus antiarrhythmic therapy on outcomes have shown mixed results. In addition, guidelines recommend continuing oral anticoagulation (OAC) after ablation for those at ...
Full textLink to itemCite
Journal ArticleJACC Clin Electrophysiol · December 2019
OBJECTIVES: This study sought to describe clinical outcomes among patients with atrial fibrillation (AF) and contraindications to oral anticoagulation (OAC). BACKGROUND: Treatment with OAC prevents stroke and death in patients with AF, but may be contraind ...
Full textLink to itemCite
Journal ArticleCirculation · November 26, 2019
Cardiac thromboembolism attributed to atrial fibrillation (AF) is responsible for up to one-third of ischemic strokes. Stroke may be the first manifestation of previously undetected AF. Given the efficacy of oral anticoagulants in preventing AF-related isc ...
Full textLink to itemCite
Journal ArticleJ Clin Sleep Med · November 5, 2019
STUDY OBJECTIVES: Early evidence with transvenous phrenic nerve stimulation (PNS) demonstrates improved disease severity and quality of life (QOL) in patients with central sleep apnea (CSA). The goal of this analysis is to evaluate the complete prospective ...
Link to itemCite
Journal ArticlePacing Clin Electrophysiol · November 2019
BACKGROUND: Compared with medical therapy, catheter ablation of atrial fibrillation (AF) in patients with heart failure (HF) improves cardiovascular outcomes. Risk scores (CAAP-AF and APPLE) have been developed to predict the likelihood of AF recurrence af ...
Full textOpen AccessLink to itemCite
Journal ArticleEuropace · November 1, 2019
AIMS: Patient selection is a key component of securing optimal patient outcomes with leadless pacing. We sought to describe and compare patient characteristics and outcomes of Micra patients with and without a primary pacing indication associated with atri ...
Full textLink to itemCite
Journal ArticleJ Cardiovasc Electrophysiol · October 2019
INTRODUCTION: Little is known about how genetic predisposition and fibrosis relate in atrial fibrillation (AF). Hence, we sought to determine whether the genetic variants and biomarkers for fibrosis enhance prediction of outcomes after catheter ablation. M ...
Full textLink to itemCite
Journal ArticleAm J Cardiol · September 15, 2019
Recently, cluster analysis was used to identify unique clinically relevant phenotypes of atrial fibrillation (AF) in a cohort from the United States (US) and classified clusters according to the presence of comorbid behavioral disorders, those with conduct ...
Full textLink to itemCite
Journal ArticleJ Am Coll Cardiol · August 27, 2019
Diabetes mellitus is one of the most common chronic medical conditions, and is a risk factor for the development of atrial fibrillation (AF). The presence of diabetes in patients with AF is associated with increased symptom burden and increased cardiovascu ...
Full textLink to itemCite
Journal ArticlePacing Clin Electrophysiol · August 2019
BACKGROUND: The Micra clinical trials have enrolled more than 2500 patients without any reported device-related infections that required removal during follow-up. Leadless pacemakers might be more resistant to bacterial seeding due to smaller surface area ...
Full textLink to itemCite
Journal ArticleJAMA Cardiol · August 1, 2019
IMPORTANCE: Bleeding and thrombotic events (eg, stroke and systemic embolism) are common in patients with atrial fibrillation (AF) taking warfarin sodium despite a well-established therapeutic range. OBJECTIVE: To evaluate whether history of therapeutic wa ...
Full textLink to itemCite
Journal ArticleJACC Basic Transl Sci · August 2019
There is an increasing recognition of the importance of interactions between the heart and the autonomic nervous system in the pathophysiology of arrhythmias. These interactions play a role in both the initiation and maintenance of arrhythmias and are impo ...
Full textLink to itemCite
ConferenceJACC Cardiovasc Imaging · July 2019
OBJECTIVES: The goal of this study was to examine whether diastolic dyssynchrony, measured by using gated single-photon emission computed tomography (GSPECT) myocardial perfusion imaging (MPI) in patients with coronary artery disease (CAD), is independentl ...
Full textLink to itemCite
Journal ArticleJACC Heart Fail · July 2019
OBJECTIVES: The purpose of this study was to compare the effectiveness of bucindolol with that of metoprolol succinate for the maintenance of sinus rhythm in a genetically defined heart failure (HF) population with atrial fibrillation (AF). BACKGROUND: Buc ...
Full textLink to itemCite
Journal ArticleAm Heart J · July 2019
BACKGROUND: Treatment patterns and outcomes of individuals with vascular disease who have new-onset atrial fibrillation (AF) are not well characterized. METHODS: Among patients with new-onset AF, we analyzed treatment and outcomes in those with or without ...
Full textLink to itemCite
Journal ArticleEur Heart J · June 14, 2019
Much of medical risk prediction involves externally derived prediction equations, nomograms, and point-based risk scores. These settings are vulnerable to misleading findings of incremental value based on versions of the net reclassification index (NRI) in ...
Full textLink to itemCite
Journal ArticleJACC Heart Fail · June 2019
Heart failure and atrial fibrillation are 2 common cardiovascular disorders that frequently complicate one another and exert a significant detrimental effect on cardiovascular health and well-being. Both heart failure and atrial fibrillation continue to in ...
Full textLink to itemCite
Journal ArticleCirculation · May 28, 2019
BACKGROUND: Device-detected atrial fibrillation (AF) is associated with increased risk of stroke; however, there are no clearly defined thresholds of AF burden at which to initiate oral anticoagulation (OAC). We sought to describe OAC prescription practice ...
Full textLink to itemCite
Journal ArticleAm J Cardiol · May 15, 2019
Systolic blood pressure (SBP) and its association with clinical outcomes in atrial fibrillation (AF) patients in community practice are poorly characterized. In patients with AF, we sought to (1) examine the prevalence of baseline uncontrolled hypertension ...
Full textLink to itemCite
Journal ArticleJ Am Heart Assoc · May 7, 2019
Background Patient satisfaction with therapy is an important metric of care quality and has been associated with greater medication persistence. We evaluated the association of patient satisfaction with warfarin therapy to other metrics of anticoagulation ...
Full textLink to itemCite
Journal ArticleCardiol Clin · May 2019
Atrial fibrillation (AF) and heart failure (HF) are conditions that frequently coexist and are associated with worse outcomes compared with either condition alone. Although rhythm control with antiarrhythmic drug treatment is not superior to rate control i ...
Full textLink to itemCite
Journal ArticleAm Heart J · May 2019
BACKGROUND: The incidence of cognitive impairment and frailty increase with age and may impact both therapy and outcomes in atrial fibrillation (AF). METHODS: We examined the prevalence of clinically recognized cognitive impairment and frailty (as defined ...
Full textLink to itemCite
Journal ArticleCardiol Clin · May 2019
Atrial fibrillation (AF) and heart failure (HF) both significantly affect morbidity and mortality and also account for high symptom burden and impaired health-related quality of life (hrQoL). Several well-designed and broadly implemented patient-reported o ...
Full textLink to itemCite
Journal ArticleJACC Clin Electrophysiol · May 2019
OBJECTIVES: This study sought to determine how frequently patient-reported outcomes (PROs) are collected in registered clinical studies of atrial fibrillation (AF). BACKGROUND: Improving symptom burden and quality of life are important goals in the treatme ...
Full textLink to itemCite
Journal ArticleCirc Cardiovasc Qual Outcomes · May 2019
Background The Atrial Fibrillation Effect on Quality-of-Life (AFEQT) questionnaire has recently been validated to measure the impact of atrial fibrillation on quality of life, but a clinically important difference in AFEQT score has not been well defined. ...
Full textLink to itemCite
Journal ArticleEur Heart J · April 21, 2019
AIMS: The Catheter Ablation vs. Antiarrhythmic Drug Therapy for Atrial Fibrillation (CABANA) trial aimed to assess the impact of ablation on morbidity and mortality. This observational study was conducted in parallel to CABANA to assess trial generalizabil ...
Full textLink to itemCite
Chapter · April 5, 2019
Three-dimensional electroanatomical mapping (EAM) systems realistically made it feasible to map focal or reentrant arrhythmias from one of the cardiac chambers. The importance of optimized detailed and accurate mapping within the regions previously conside ...
Full textCite
Journal ArticleJAMA · April 2, 2019
IMPORTANCE: Catheter ablation is more effective than drug therapy in restoring sinus rhythm in patients with atrial fibrillation (AF), but its incremental effect on long-term quality of life (QOL) is uncertain. OBJECTIVE: To determine whether catheter abla ...
Full textLink to itemCite
Journal ArticleJAMA · April 2, 2019
IMPORTANCE: Catheter ablation is effective in restoring sinus rhythm in atrial fibrillation (AF), but its effects on long-term mortality and stroke risk are uncertain. OBJECTIVE: To determine whether catheter ablation is more effective than conventional me ...
Full textOpen AccessLink to itemCite
Journal ArticleEur Heart J Qual Care Clin Outcomes · April 1, 2019
AIMS: The management of anticoagulation therapy in patients with atrial fibrillation (AF) and cancer is challenging due to increased thrombotic and bleeding risks. We sought to determine the safety and efficacy of rivaroxaban in patients with AF and a hist ...
Full textLink to itemCite
Journal ArticleJ Cardiovasc Electrophysiol · April 2019
INTRODUCTION: Leadless pacemakers may provide a safe and attractive pacing option to patients with cardiac implantable electronic device (CIED) infection. We describe the characteristics and outcomes of patients with a recent CIED infection undergoing Micr ...
Full textLink to itemCite
Journal ArticleJACC Cardiovasc Interv · March 25, 2019
OBJECTIVES: The aim of this study was to compare 1-year outcomes following transcatheter mitral valve (MV) repair in patients with and without atrial fibrillation (AF). BACKGROUND: The development of AF in degenerative mitral regurgitation (MR) is consider ...
Full textLink to itemCite
Journal ArticleCirculation · March 19, 2019
BACKGROUND: Efforts to improve prescription of oral anticoagulation (OAC) drugs in patients with atrial fibrillation have had limited success in improving guideline adherence. METHODS: We evaluated adherence to the American College of Cardiology/American H ...
Full textLink to itemCite
Journal ArticleHeart · March 2019
OBJECTIVE: The association with B-type natriuretic peptide (BNP), disease progression and outcomes in patients with atrial fibrillation (AF) has not been thoroughly investigated. METHODS: We evaluated the association between BNP levels and outcomes, includ ...
Full textLink to itemCite
Journal ArticleEuropace · March 1, 2019
AIMS: Atrial fibrillation (AF) is associated with increased mortality, but the temporal relationship between AF burden (AFB) and death among patients with cardiac implanted electronic devices is unknown. We sought to characterize the timing and progression ...
Full textLink to itemCite
Journal ArticleHeart Rhythm · February 2019
BACKGROUND: Postoperative atrial fibrillation (POAF) frequently complicates cardiac surgery and is associated with worse outcomes. The cardiac autonomic nervous system is implicated in the pathogenesis of POAF. OBJECTIVE: The purpose of this study was to d ...
Full textLink to itemCite
Journal ArticleJACC Clin Electrophysiol · February 2019
OBJECTIVES: This study sought to report periprocedural outcomes and intermediate-term follow-up of hemodialysis patients undergoing Micra implantation. BACKGROUND: Leadless pacemakers may be preferred in patients with limited vascular access and high-infec ...
Full textLink to itemCite
Journal ArticleHeart Rhythm · January 2019
BACKGROUND: Patients with heart failure and sleep apnea are at increased risk for developing arrhythmias. Whether treatment of sleep apnea reduces arrhythmias is unknown. OBJECTIVE: The purpose of this study was to determine whether adaptive servo-ventilat ...
Full textLink to itemCite
Journal ArticleInt J Cardiol · January 1, 2019
BACKGROUND: Renal function has been associated with an increased stroke risk in patients with atrial fibrillation (AF). However, whether renal function incrementally adds to risk prediction in both anticoagulated and non-anticoagulated patients with AF is ...
Full textLink to itemCite
Journal ArticleHeart Rhythm · January 2019
BACKGROUND: Atrial fibrillation (AF) affects an estimated 33 million people worldwide, leading to increased mortality and an increased risk of heart failure and stroke. Many AF patient registries exist, but the ability to link and compare data across regis ...
Full textLink to itemCite
Journal ArticleJ Cardiothorac Vasc Anesth · January 2019
Postoperative atrial fibrillation (poAF) is the most common adverse event after cardiac surgery and is associated with increased morbidity, mortality, and increased hospital and intensive care unit length of stay. Despite progressive improvements in overal ...
Full textLink to itemCite
Journal ArticleAnesth Analg · January 2019
Postoperative atrial fibrillation (poAF) is the most common adverse event after cardiac surgery and is associated with increased morbidity, mortality, and hospital and intensive care unit length of stay. Despite progressive improvements in overall cardiac ...
Full textLink to itemCite
Journal ArticleHeart Rhythm · December 2018
BACKGROUND: Early results of the Micra Investigational Device Exemption (IDE) study and Micra Post-Approval Registry (PAR) demonstrated excellent safety and efficacy performance; however, intermediate-term results across a large patient population in the r ...
Full textLink to itemCite
Journal ArticleNat Rev Cardiol · December 2018
Atrial fibrillation (AF) is the most common arrhythmia in adults, and its incidence and prevalence increase with age. The risk of cognitive impairment and dementia also increases with age, and both AF and cognitive impairment or dementia share important ri ...
Full textLink to itemCite
Journal ArticleJAMA Cardiol · December 1, 2018
IMPORTANCE: Black and Hispanic patients are less likely than white patients to use oral anticoagulants for atrial fibrillation. Little is known about racial/ethnic differences in use of direct-acting oral anticoagulants (DOACs) for atrial fibrillation. OBJ ...
Full textLink to itemCite
Journal ArticleAm J Cardiol · November 15, 2018
Asymptomatic atrial fibrillation (AF) is being increasingly diagnosed via implantable devices, screening, and inpatient telemetry. Management of asymptomatic AF is controversial, in part, because the associated risks have not been well described. We examin ...
Full textLink to itemCite
Journal ArticleEuropace · November 1, 2018
AIMS: To assess whether obstructive sleep apnea (OSA) was associated with increased rotor burden among atrial fibrillation (AF) patients. METHODS AND RESULTS: We studied 33 consecutive patients who were scheduled for focal impulse and rotor modulation (FIR ...
Full textLink to itemCite
Journal ArticleHeart · November 2018
OBJECTIVE: Chronic obstructive pulmonary disease (COPD) is associated with the development of atrial fibrillation (AF), and may complicate treatment of AF. We examined the association between COPD and symptoms, quality of life (QoL), treatment and outcomes ...
Full textLink to itemCite
Journal ArticleJ Thromb Thrombolysis · November 2018
Anticoagulation is highly effective for the prevention of stroke in patients with atrial fibrillation (AF) but it is dependent on patients continuing therapy. While studies have demonstrated suboptimal therapeutic persistence on warfarin, few have studied ...
Full textLink to itemCite
Journal ArticleEuropace · October 1, 2018
AIMS: Implantable cardioverter-defibrillators (ICDs) are key in the prevention of sudden cardiac death, but outcomes may vary by type of device or programming [single chamber (SC) vs. dual chamber (DC)] in patients without a bradycardia pacing indication. ...
Full textLink to itemCite
Journal ArticleCirc Heart Fail · October 2018
BACKGROUND: Stroke prophylaxis in patients with atrial fibrillation (AF) and heart failure (HF) in the era of direct oral anticoagulants is not well characterized. Using data from American Heart Association Get With The Guidelines-AFIB, we sought to evalua ...
Full textLink to itemCite
Journal ArticleJ Am Heart Assoc · September 18, 2018
Background Chronic kidney disease ( CKD ) is a common comorbidity in patients with atrial fibrillation. The presence of CKD complicates drug selection for stroke prevention and rhythm control. Methods and Results Patients enrolled in ORBIT AF (Outcomes Reg ...
Full textLink to itemCite
Journal ArticleJACC Cardiovasc Interv · September 10, 2018
OBJECTIVES: The aim of this study was to evaluate incidence, care patterns, and clinical outcomes in patients developing new-onset atrial fibrillation (AF) following transcatheter aortic valve replacement (TAVR). BACKGROUND: Pre-procedural AF has been asso ...
Full textLink to itemCite
Journal ArticleCirculation · August 28, 2018
BACKGROUND: Bleeding is commonly cited as a reason for stopping oral anticoagulants (OACs). Whether minor bleeding events (nuisance bleeding, NB) in patients with atrial fibrillation on OACs are associated with OAC discontinuation, major bleeding, and stro ...
Full textLink to itemCite
Journal ArticleEur Heart J · August 21, 2018
AIMS: It is recommended to perform atrial fibrillation ablation with continuous anticoagulation. Continuous apixaban has not been tested. METHODS AND RESULTS: We compared continuous apixaban (5 mg b.i.d.) to vitamin K antagonists (VKA, international normal ...
Full textLink to itemCite
Journal ArticleJ Am Heart Assoc · August 21, 2018
Background Current American College of Cardiology/American Heart Association guidelines suggest that for patients with atrial fibrillation who are at low risk for stroke (CHA2DS2VASc=1) (or women with CHA2DS2VASc=2) a variety of treatment strategies may be ...
Full textOpen AccessLink to itemCite
ConferenceJ Am Heart Assoc · August 7, 2018
Background There is concern that selective serotonin reuptake inhibitors ( SSRI s) substantially increase bleeding risk in patients taking anticoagulants. Methods and Results We studied 737 patients taking SSRI s in the ROCKET AF (Rivaroxaban Once Daily Or ...
Full textLink to itemCite
Journal ArticleJ Am Coll Cardiol · August 7, 2018
BACKGROUND: Ventricular tachycardia (VT) and ventricular fibrillation (VF) remain a challenging problem in patients with implantable cardioverter-defibrillators (ICDs). OBJECTIVES: This study aimed to determine whether ranolazine administration decreases t ...
Full textLink to itemCite
Journal ArticleCan J Anaesth · July 2018
PURPOSE: The Multicenter Study of Perioperative Ischemia (McSPI) AFRisk index predicts postoperative atrial fibrillation (POAF) after cardiac surgery, but requires pre-, intra-, and postoperative data. Other more abbreviated risk indices exist, but there i ...
Full textLink to itemCite
Journal ArticleJ Am Heart Assoc · June 9, 2018
BACKGROUND: Oral anticoagulation (OAC) reduces stroke risk in atrial fibrillation, but bleeding is a frequent side effect. The decision to discontinue or modify medication regimens in response to a bleeding event may differ according to bleeding site and s ...
Full textLink to itemCite
Journal ArticleAm Heart J · June 2018
BACKGROUND: We investigated the impact of polyvascular disease in patients enrolled in ROCKET AF. METHODS: Cox regression models were used to assess clinical outcomes and treatment effects of rivaroxaban compared with warfarin in patients with atrial fibri ...
Full textLink to itemCite
Journal ArticleHeart Rhythm · May 2018
BACKGROUND: Few studies have examined outcomes of catheter ablation for atrial fibrillation (AF) in patients with heart failure (HF) with preserved ejection fraction (HFpEF). OBJECTIVE: The purpose of this study was to compare outcomes of AF ablation in pa ...
Full textLink to itemCite
Journal ArticleAm Heart J · May 2018
BACKGROUND: Few therapies are available for the safe and effective treatment of atrial fibrillation (AF) in patients with heart failure. Bucindolol is a non-selective beta-blocker with mild vasodilator activity previously found to have accentuated antiarrh ...
Full textLink to itemCite
Journal ArticleInt J Cardiol · April 15, 2018
AIMS: The aim of this study was to determine the net clinical benefit (NCB) of rivaroxaban compared with warfarin in patients with atrial fibrillation. METHODS: This was a retrospective analysis of 14,236 patients included in ROCKET AF who received at leas ...
Full textLink to itemCite
Journal ArticleJ Am Heart Assoc · April 13, 2018
BACKGROUND: Mineralocorticoid receptor antagonist (MRA) therapy may be beneficial to patients with atrial fibrillation (AF), but little is known about their use in patients with AF and subsequent outcomes. METHODS AND RESULTS: In order to better understand ...
Full textLink to itemCite
Journal ArticleHeart · March 2018
OBJECTIVE: To describe self-reported disease understanding for newly diagnosed patients with atrial fibrillation (AF) and assess (1) how disease understanding changes over the first 6 months after diagnosis and (2) the relationship between patient understa ...
Full textLink to itemCite
Journal ArticleJ Am Heart Assoc · February 16, 2018
BACKGROUND: Non-vitamin K antagonist oral anticoagulants (NOACs) are indicated for stroke prevention in atrial fibrillation (AF) but require lower doses in certain patients. We sought to describe the frequency, appropriateness (according to Food and Drug A ...
Full textLink to itemCite
Journal ArticleCurr Treat Options Cardiovasc Med · January 25, 2018
Catheter ablation (CA) for atrial fibrillation (AF) is an established first-line approach to the management of drug-refractory AF. Although, advancements in procedural techniques and technology have improved the efficacy and safety of CA, thromboembolism ( ...
Full textLink to itemCite
Journal ArticleJAMA · January 23, 2018
IMPORTANCE: The left atrial appendage is a key site of thrombus formation in atrial fibrillation (AF) and can be occluded or removed at the time of cardiac surgery. There is limited evidence regarding the effectiveness of surgical left atrial appendage occ ...
Full textLink to itemCite
Journal ArticleJACC Clin Electrophysiol · January 2018
OBJECTIVES: In this study, the authors sought to perform a meta-analysis of controlled studies assessing the relationship between left atrial appendage (LAA) electrical isolation (EI) and recurrent atrial fibrillation (AF). BACKGROUND: LAA triggers could p ...
Full textLink to itemCite
Journal ArticleJAMA Cardiol · January 1, 2018
IMPORTANCE: Atrial fibrillation (AF) is usually classified on the basis of the disease subtype. However, this characterization does not capture the full heterogeneity of AF, and a data-driven cluster analysis reveals different possible classifications of p ...
Full textLink to itemCite
Journal ArticleClin Cardiol · January 2018
BACKGROUND: Atrial fibrillation (AF) increases risk of stroke 5-fold. Carotid artery disease (CD) also augments the risk of stroke, yet there are limited data about the interplay of these 2 diseases and clinical outcomes in patients with comorbid AF and CD ...
Full textLink to itemCite
Journal ArticleJ Am Heart Assoc · December 22, 2017
BACKGROUND: The presence of valvular heart disease (VHD) may affect the risk of stroke and mortality in patients with atrial fibrillation (AF). Community-based estimates of prevalence and outcomes of specific forms of VHD in patients with AF are lacking. M ...
Full textLink to itemCite
Journal ArticleBMJ Open · December 21, 2017
OBJECTIVES: To provide an accurate, web-based tool for stratifying patients with atrial fibrillation to facilitate decisions on the potential benefits/risks of anticoagulation, based on mortality, stroke and bleeding risks. DESIGN: The new tool was develop ...
Full textLink to itemCite
Journal ArticleJ Cardiovasc Electrophysiol · December 2017
INTRODUCTION: Treatment refractory ventricular arrhythmias (VAs) are often driven and exacerbated by heightened sympathetic tone. We aim to conduct a systematic review and meta-analysis of published studies of a temporary percutaneous stellate ganglion blo ...
Full textLink to itemCite
Journal ArticleCurr Heart Fail Rep · December 2017
PURPOSE OF REVIEW: We explore the pharmacogenomics of the beta-blocker bucindolol by discussing relevant beta-1 adrenergic receptor (ADRB1) polymorphisms and recent beta-blocker studies. Through this, we will understand how bucindolol may help patients wit ...
Full textLink to itemCite
Journal ArticleAm Heart J · December 2017
UNLABELLED: Atrial fibrillation (AF) is the most common cardiac arrhythmia in the world. We aimed to provide comprehensive data on international patterns of AF stroke prevention treatment. METHODS: Demographics, comorbidities, and stroke risk of the patien ...
Full textLink to itemCite
Journal ArticleAm J Cardiol · November 15, 2017
The safety of intravenous thrombolysis in patients taking rivaroxaban has not been well established. We retrospectively analyzed the outcomes of all patients who received thrombolytic therapy in the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition C ...
Full textLink to itemCite
Journal ArticleCirc Arrhythm Electrophysiol · November 2017
BACKGROUND: It is unclear how frequently patients with atrial fibrillation receive guideline-concordant (GC) care and whether guideline concordance is associated with improved outcomes. METHODS AND RESULTS: Using data from ORBIT-AF (Outcomes Registry for B ...
Full textLink to itemCite
Journal ArticleEuropace · November 1, 2017
Atrial fibrillation (AF) is a major worldwide public health problem, and AF in association with valvular heart disease (VHD) is also common. However, management strategies for this group of patients have been less informed by randomized trials, which have ...
Full textLink to itemCite
Journal ArticleCirculation · October 10, 2017
BACKGROUND: Lead management is an increasingly important aspect of care in patients with cardiac implantable electronic devices; however, relatively little is known about long-term outcomes after capping and abandoning leads. METHODS: Using the 5% Medicare ...
Full textLink to itemCite
Journal ArticleThe American journal of cardiology · October 2017
Although higher detection rates and delayed detection improve survival in implantable cardioverter defibrillator clinical trials, their effectiveness in clinical practice has limited validation. To evaluate the effectiveness of programming strategies for r ...
Full textCite
Journal ArticleJ Am Coll Cardiol · September 12, 2017
BACKGROUND: Diabetes is a well-established risk factor for thromboembolism in patients with atrial fibrillation (AF), but less is known about how diabetes influences outcomes among AF patients. OBJECTIVES: This study assessed whether symptoms, health statu ...
Full textLink to itemCite
Journal ArticleHeart Rhythm · September 2017
BACKGROUND: Atrioesophageal fistula formation is a rare but life-threatening complication of atrial fibrillation ablation. Contact force (CF)-sensing catheters improve procedural effectiveness. However, the impact of the implementation of CF-sensing techno ...
Full textLink to itemCite
Journal ArticleClin Cardiol · September 2017
BACKGROUND: Oral anticoagulation (OAC) therapy is associated with increased periprocedural risks after cardiac implantable electronic device (CIED) implantation. Patterns of anticoagulation management involving non-vitamin K antagonist oral anticoagulants ...
Full textLink to itemCite
ConferenceAm J Cardiol · August 15, 2017
Non-dihydropyridine calcium channel blockers (non-DHP CCBs) possess combined P-glycoprotein and moderate CYP3A4 inhibition, which may lead to increased exposure of medications that are substrates for these metabolic pathways, such as rivaroxaban. We evalua ...
Full textLink to itemCite
Journal ArticleThromb Res · August 2017
BACKGROUND: The ROCKET AF study evaluated once-daily rivaroxaban versus dose-adjusted warfarin for the prevention of stroke and systemic embolism in patients with atrial fibrillation (AF). In this analysis, we compared rivaroxaban with warfarin in patients ...
Full textLink to itemCite
Journal ArticleEur Heart J · July 14, 2017
In 2013, the European Heart Rhythm Association (EHRA) published a Practical Guide on the use of non-VKA oral anticoagulants (NOACs) in patients with atrial fibrillation (AF) (Heidbuchel H, Verhamme P, Alings M, Antz M, Hacke W, Oldgren J, Sinnaeve P, Camm ...
Full textLink to itemCite
Journal ArticleEuropace · July 1, 2017
AIMS: Antiarrhythmic medications for the treatment of atrial fibrillation (AF) have limited efficacy and rare but potentially life-threatening side effects. Ranolazine is an antianginal agent that may have antiarrhythmic activity in AF. METHODS AND RESULTS ...
Full textLink to itemCite
Journal ArticleAm Heart J · July 2017
BACKGROUND: Several non-vitamin K antagonist oral anticoagulant (NOAC) alternatives to warfarin are available for stroke prevention in atrial fibrillation (AF). We aimed to describe the factors associated with selection of NOACs versus warfarin in patients ...
Full textLink to itemCite
Journal ArticleEur Heart J Qual Care Clin Outcomes · July 1, 2017
AIMS: The presence of cancer can complicate treatment choices for patients with atrial fibrillation (AF) increasing both the risk of thrombotic and bleeding events. METHODS AND RESULTS: Using data from Outcomes Registry for Better Informed Treatment of Atr ...
Full textOpen AccessLink to itemCite
Journal ArticleAm J Cardiol · June 15, 2017
We investigated stroke outcomes in normal weight (body mass index [BMI] 18.50 to 24.99 kg/m2), overweight (BMI 25.00 to 29.99 kg/m2), and obese (BMI ≥30 kg/m2) patients with atrial fibrillation treated with rivaroxaban and warfarin. We compared the inciden ...
Full textLink to itemCite
Journal ArticleJ Am Heart Assoc · June 14, 2017
BACKGROUND: Although implantation of cardiac implantable electronic devices (CIEDs) in patients receiving warfarin is well studied, limited data are available on the use of oral factor Xa inhibitors in this setting. METHODS AND RESULTS: Using data from Riv ...
Full textLink to itemCite
Journal ArticleAm J Cardiol · June 1, 2017
The degree to which clinical outcomes are worsened in patients with atrial fibrillation (AF) with heart failure (HF) compared with those without HF is not well described. This study aimed to determine the impact of HF on clinical outcomes in patients with ...
Full textLink to itemCite
Journal ArticleAm J Cardiol · May 15, 2017
Non-vitamin K antagonist oral anticoagulants (NOACs) are effective at preventing stroke in patients with atrial fibrillation (AF). However, little is known about the management of bleeding in contemporary, clinical use of NOACs. We aimed to assess the freq ...
Full textLink to itemCite
Journal ArticleJ Am Heart Assoc · May 10, 2017
BACKGROUND: Whether outcomes differ between sexes following treatment with pacemakers (PM), implantable cardioverter defibrillators, and cardiac resynchronization therapy (CRT) devices is unclear. METHODS AND RESULTS: Consecutive US patients with newly imp ...
Full textLink to itemCite
Journal ArticleCirculation · May 9, 2017
Approximately 10% of ischemic strokes are associated with atrial fibrillation (AF) first diagnosed at the time of stroke. Detecting asymptomatic AF would provide an opportunity to prevent these strokes by instituting appropriate anticoagulation. The AF-SCR ...
Full textLink to itemCite
Journal ArticleHeart Rhythm · May 2017
BACKGROUND: Device repositioning during Micra leadless pacemaker implantation may be required to achieve optimal pacing thresholds. OBJECTIVE: The purpose of this study was to describe the natural history of acute elevated Micra vs traditional transvenous ...
Full textLink to itemCite
Journal ArticleAm Heart J · May 2017
This white paper, prepared by members of the Cardiac Safety Research Consortium (CSRC), discusses important issues regarding scientific and clinical aspects of long-term electrocardiographic safety monitoring during clinical drug development. To promote mu ...
Full textLink to itemCite
Journal ArticleAm J Med · April 2017
BACKGROUND: Prior studies have shown a treatment gap in oral anticoagulation (OAC) use among patients with atrial fibrillation yet have incompletely characterized factors associated with failure to treat and subsequent outcomes in contemporary practice. ME ...
Full textLink to itemCite
Journal ArticleJ Cardiovasc Electrophysiol · April 2017
Ventricular tachycardia (VT), ventricular fibrillation (VF), and electrical storm are commonly encountered emergency conditions in cardiac and surgical intensive care units. In most cases, recurrent ventricular arrhythmias or electrical storm are associate ...
Full textLink to itemCite
Journal ArticleAJR Am J Roentgenol · April 2017
OBJECTIVE: Five percent of cardiac implantable electric devices (CIEDs) are removed each year. Percutaneous extraction is preferred but can be complicated if the leads adhere to the vasculature or perforate. The goal of this study is to assess the frequenc ...
Full textLink to itemCite
Journal ArticlePacing Clin Electrophysiol · April 2017
BACKGROUND: Symptomatic sinus node dysfunction (SND) consists of a variety of manifestations, including tachycardia-bradycardia syndrome. Atrial fibrillation (AF) is commonly associated with SND, which complicates the management of both conditions. This pa ...
Full textLink to itemCite
Journal ArticleEur Heart J · March 21, 2017
Atrial fibrillation (AF) is a worldwide epidemic associated with significant morbidity and mortality, often due to disabling or fatal thromboembolic stroke. Oral anticoagulation is highly effective at preventing ischaemic stroke and improving all-cause sur ...
Full textLink to itemCite
Journal ArticleCirculation · March 7, 2017
Non-vitamin K oral anticoagulants (NOACs) are now widely used as alternatives to warfarin for stroke prevention in atrial fibrillation and management of venous thromboembolism. In clinical practice, there is still widespread uncertainty on how to manage pa ...
Full textLink to itemCite
Journal ArticleJAMA Cardiol · March 1, 2017
IMPORTANCE: The joint American College of Cardiology (ACC), American Heart Association (AHA), and Heart Rhythm Society (HRS) guidelines on the management of atrial fibrillation (AF) are used extensively to guide patient care. OBJECTIVE: To describe the evi ...
Full textLink to itemCite
Journal ArticleAm Heart J · March 2017
UNLABELLED: Cardioversion is a class I procedure for patients with symptomatic atrial fibrillation (AF) pursuing rhythm control. There are few contemporary reports on quality of life and outcomes after cardioversion. METHODS: Using the nationwide prospecti ...
Full textLink to itemCite
Journal ArticleJACC Clin Electrophysiol · February 2017
OBJECTIVES: In this study, the authors performed a meta-analysis of currently available comparative prospective studies to assess the efficacy and safety of exercise training in heart failure (HF) patients with implantable cardioverter-defibrillators (ICD) ...
Full textLink to itemCite
Journal ArticleJ Cardiovasc Electrophysiol · January 2017
INTRODUCTION: Data regarding catheter ablation of atrial fibrillation (AF) in patients with chronic kidney disease (CKD) is limited. We therefore assessed the association of CKD with common safety and clinical outcomes in a nationwide sample of ablation re ...
Full textLink to itemCite
Journal ArticleJACC Heart Fail · January 2017
OBJECTIVES: The purpose of this study was to determine the significant clinical predictors of incident heart failure (HF) and its prognostic effect on long-term outcomes among community-based patients with established atrial fibrillation (AF). BACKGROUND: ...
Full textLink to itemCite
Journal ArticleEuropace · January 2017
AIMS: Catheter ablation is the most efficacious rhythm control therapy in atrial fibrillation (AF) patients. There is growing evidence that catheter ablation procedures are best performed during continuous oral anticoagulation, but outcomes are variable de ...
Full textLink to itemCite
Journal ArticleJ Am Coll Cardiol · December 20, 2016
BACKGROUND: Although non-vitamin K antagonist oral anticoagulants (NOACs) do not require frequent laboratory monitoring, each compound requires dose adjustments on the basis of certain clinical criteria. OBJECTIVES: This study assessed the frequency of off ...
Full textLink to itemCite
Journal ArticleAm Heart J · December 2016
BACKGROUND: As treatment options for atrial fibrillation (AF) increase, more attention is focused on patients' experiences and quality of life (QoL). However, little is known about the factors associated with these outcomes. METHODS: The Atrial Fibrillatio ...
Full textLink to itemCite
Journal ArticleHeart Rhythm · December 2016
BACKGROUND: Remote monitoring (RM) of cardiac implantable electronic devices (CIEDs) improves patient survival. However, whether RM reduces health care utilization is unknown. OBJECTIVE: The purpose of this study was to determine whether RM was associated ...
Full textLink to itemCite
Journal ArticleJ Am Heart Assoc · November 19, 2016
BACKGROUND: We examined all-cause mortality and long-term thromboembolic risk (ischemic stroke, transient ischemic attack, systemic thromboembolism) in patients with and without familial atrial fibrillation (AF). METHODS AND RESULTS: Using Danish nationwid ...
Full textOpen AccessLink to itemCite
Journal ArticleAm Heart J · November 2016
BACKGROUND: Assessments of stroke and bleeding risks are essential to selecting oral anticoagulation in patients with atrial fibrillation (AF). We aimed to assess outcomes according to physician assessed risk, with comparison to empirical risk scores. METH ...
Full textLink to itemCite
Journal ArticleJACC Clin Electrophysiol · November 2016
OBJECTIVE: To explore gender differences in real-world outcomes after catheter ablation of atrial fibrillation (AF). BACKGROUND: Compared to men, women with AF have greater thromboembolic risk and tend to be more symptomatic. Catheter ablation is generally ...
Full textLink to itemCite
Journal ArticleAm J Med · October 2016
BACKGROUND: Non-vitamin K oral anticoagulants (NOACs) are proven alternatives to vitamin K antagonists (VKAs) for the prevention of thromboembolism in patients with nonvalvular atrial fibrillation. However, there are few data on the efficacy and safety of ...
Full textLink to itemCite
Journal ArticleHeart Rhythm · September 2016
BACKGROUND: Vanoxerine is an oral, 1,4-dialkylpiperazine derivative antiarrhythmic drug being evaluated for pharmacological cardioversion of atrial fibrillation (AF). OBJECTIVE: The purpose of this study was to evaluate the safety and efficacy of vanoxerin ...
Full textLink to itemCite
Journal ArticleAm Heart J · September 2016
BACKGROUND: We aimed to investigate the relationship between aspirin use and clinical outcomes in patients enrolled in Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in ...
Full textLink to itemCite
Journal ArticleClin Cardiol · September 2016
Associations between atrial fibrillation (AF), outcomes, and response to antiplatelet therapies in patients with acute coronary syndrome (ACS) managed medically without revascularization remain uncertain. We examined these associations for medically manage ...
Full textLink to itemCite
Journal ArticleJACC Cardiovasc Interv · August 22, 2016
OBJECTIVES: The authors assessed the use of dual antiplatelet therapy (DAPT) and outcomes in patients undergoing percutaneous coronary intervention (PCI) during the ROCKET AF (Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K ...
Full textLink to itemCite
Journal ArticleLancet · August 20, 2016
Many patients with atrial fibrillation have substantial symptoms despite ventricular rate control and require restoration of sinus rhythm to improve their quality of life. Acute restoration (ie, cardioversion) and maintenance of sinus rhythm in patients wi ...
Full textLink to itemCite
Journal ArticleJ Interv Card Electrophysiol · August 2016
PURPOSE: Guidelines advocate remote monitoring (RM) in patients with a cardiac implantable electronic device (CIED). However, it is not known when RM should be initiated. We hypothesized that prompt initiation of RM (within 91 days of implant) is associate ...
Full textLink to itemCite
Journal ArticleTrends Cardiovasc Med · August 2016
With increasing indications and access to cardiac implantable electronic devices (CIEDs) worldwide, the number of patients needing CIED follow-up continues to rise. In parallel, the technology available for managing these devices has advanced considerably. ...
Full textLink to itemCite
Journal ArticleEuropace · August 2016
AIMS: The high costs associated with treatment for atrial fibrillation (AF) are primarily due to hospital care, but there are limited data to understand the reasons for and predictors of hospitalization in patients with AF. METHODS AND RESULTS: The ROCKET ...
Full textLink to itemCite
Journal ArticleAm Heart J · August 2016
BACKGROUND: We conducted a retrospective analysis examining the association between systolic blood pressure (SBP) or hypertension bracket and stroke risk in patients with atrial fibrillation (AF). METHODS: The study included 14,256 anticoagulated patients ...
Full textLink to itemCite
Journal ArticleCirculation · July 5, 2016
BACKGROUND: Despite rapid clinical adoption of novel anticoagulants, it is unknown whether outcomes differ among patients with worsening renal function (WRF) taking these new drugs compared with warfarin. We aimed to determine whether the primary efficacy ...
Full textLink to itemCite
Journal ArticleHeart · July 1, 2016
OBJECTIVE: To compare the characteristics and outcomes of patients with atrial fibrillation (AF) and aortic stenosis (AS) with patients with AF with mitral regurgitation (MR) or aortic regurgitation (AR) and patients without significant valve disease (no S ...
Full textLink to itemCite
Journal ArticleJ Am Coll Cardiol · June 21, 2016
Nonvitamin K-dependent oral anticoagulant agents (NOACs) are currently recommended for patients with atrial fibrillation at risk for stroke. As a group, NOACs significantly reduce stroke, intracranial hemorrhage, and mortality, with lower to similar major ...
Full textLink to itemCite
Journal ArticleAm J Med · June 2016
BACKGROUND: The role of triple antithrombotic therapy vs dual antithrombotic therapy in patients with both atrial fibrillation and coronary artery disease remains unclear. This study explores the differences in treatment practices and outcomes between trip ...
Full textLink to itemCite
Journal ArticleHeart Rhythm · June 2016
BACKGROUND: The Medtronic model 4195 (StarFix) left ventricular lead is an active fixation lead that provides additional support within the coronary sinus (CS) via deployable lobes. While this lead has been shown to have excellent stability within the CS, ...
Full textLink to itemCite
Journal ArticleCirc Heart Fail · June 2016
BACKGROUND: Atrial fibrillation is common in patients with heart failure, but outcomes of patients with both conditions who receive cardiac resynchronization therapy with defibrillator (CRT-D) compared with an implantable cardioverter-defibrillator (ICD) a ...
Full textLink to itemCite
Journal ArticleJAMA Cardiol · June 1, 2016
IMPORTANCE: Despite the frequency of atrial fibrillation (AF) in clinical practice, relatively little is known about sex differences in symptoms and quality of life and how they may affect treatment and outcomes. OBJECTIVE: To determine whether symptoms, q ...
Full textLink to itemCite
Journal ArticleJACC Clin Electrophysiol · June 2016
OBJECTIVES: This study sought to determine the association between body mass index (BMI) and clinical outcomes among patients with prevalent atrial fibrillation (AF). BACKGROUND: Higher BMI is an independent risk factor for incident AF. However, its impact ...
Full textLink to itemCite
Journal ArticleJ Am Heart Assoc · May 4, 2016
BACKGROUND: Whereas insurance status has been previously associated with care patterns, little is currently known about the association between Medicaid insurance and the clinical characteristics, treatment, or outcomes of patients with atrial fibrillation ...
Full textOpen AccessLink to itemCite
Journal ArticleAm Heart J · May 2016
BACKGROUND: We addressed whether patients with a family history of atrial fibrillation (AF) were diagnosed as having AF earlier in life, were more symptomatic, and had worse outcomes compared with those without a family history of AF. METHODS: Using the OR ...
Full textLink to itemCite
Journal ArticleEuropace · May 2016
AIMS: Atrial fibrillation (AF) is associated with increased morbidity and mortality. Determination and quantification of familial risk may help identify high-risk patients. METHODS AND RESULTS: Using Danish nationwide registry data (1978-2012), we identifi ...
Full textLink to itemCite
Journal ArticleAm Heart J · April 2016
BACKGROUND: Significant racial/ethnic differences exist in the incidence of atrial fibrillation (AF). However, less is known about racial/ethnic differences in quality of life (QoL), treatment, and outcomes associated with AF. METHODS: Using data from the ...
Full textLink to itemCite
Journal ArticleJACC Clin Electrophysiol · April 2016
OBJECTIVES: The study sought to evaluate clinical outcomes in clinical practice with rhythm control versus rate control strategy for management of atrial fibrillation (AF). BACKGROUND: Randomized trials have not demonstrated significant differences in stro ...
Full textLink to itemCite
Journal ArticleJAMA Cardiol · April 1, 2016
IMPORTANCE: In the current therapeutic era, the risk for sudden cardiac death (SCD) after non-ST-segment elevation acute coronary syndrome (NSTE ACS) has not been characterized completely. OBJECTIVE: To determine the cumulative incidence of SCD during long ...
Full textLink to itemCite
Journal ArticleJ Am Heart Assoc · March 8, 2016
BACKGROUND: Atrial fibrillation is associated with higher mortality. Identification of causes of death and contemporary risk factors for all-cause mortality may guide interventions. METHODS AND RESULTS: In the Rivaroxaban Once Daily Oral Direct Factor Xa I ...
Full textLink to itemCite
Journal ArticleJ Thromb Thrombolysis · February 2016
Over the past several years, non-vitamin K oral anticoagulants (NOACs) have been introduced into clinical practice for the treatment of venous thromboembolism and prevention of stroke in patients with nonvalvular atrial fibrillation. Clinical trials have s ...
Full textLink to itemCite
Journal ArticleClin Cardiol · February 2016
BACKGROUND: Patients with sinus node dysfunction (SND) have increased risk of atrial tachyarrhythmias, including atrial fibrillation (AF). To date, treatment patterns and outcomes of patients with SND and AF have not been well described. HYPOTHESIS: Patien ...
Full textOpen AccessLink to itemCite
Journal ArticleCirculation · January 26, 2016
BACKGROUND: Patients with atrial fibrillation (AF) often take multiple medications. METHODS AND RESULTS: We examined characteristics and compared adjusted outcomes between rivaroxaban and warfarin according to number of concomitant baseline medications and ...
Full textLink to itemCite
Journal ArticleEuropace · January 2016
At least 30 million people worldwide carry a diagnosis of atrial fibrillation (AF), and many more suffer from undiagnosed, subclinical, or 'silent' AF. Atrial fibrillation-related cardiovascular mortality and morbidity, including cardiovascular deaths, hea ...
Full textLink to itemCite
Journal ArticleAm Heart J · January 2016
UNLABELLED: Non-ST-segment myocardial infarction (NSTEMI) can be complicated by high-degree atrioventricular (AV) block, asystole, or electromechanical dissociation (EMD), but these events are not well characterized in the contemporary era. This analysis a ...
Full textLink to itemCite
Journal ArticleEur Heart J · December 7, 2015
BACKGROUND: Therapeutic decisions in atrial fibrillation (AF) are often influenced by assessment of bleeding risk. However, existing bleeding risk scores have limitations. OBJECTIVES: We sought to develop and validate a novel bleeding risk score using rout ...
Full textOpen AccessLink to itemCite
Journal ArticleEur Heart J · December 7, 2015
Heart failure (HF) and atrial fibrillation (AF) are two conditions that are likely to dominate the next 50 years of cardiovascular (CV) care. Both are increasingly prevalent and associated with high morbidity, mortality, and healthcare cost. They are close ...
Full textLink to itemCite
Journal ArticleEuropean heart journal · December 7, 2015
BACKGROUND: Therapeutic decisions in atrial fibrillation (AF) are often influenced by assessment of bleeding risk. However, existing bleeding risk scores have limitations. ...
Full textCite
Journal ArticleJ Interv Card Electrophysiol · December 2015
PURPOSE: Cardiac resynchronization therapy (CRT) improves outcomes in patients with heart failure, yet response rates are variable. We sought to determine whether physician-specified CRT programming was associated with improved outcomes. METHODS: Using dat ...
Full textLink to itemCite
Journal ArticleJ Am Coll Cardiol · December 1, 2015
BACKGROUND: Gastrointestinal (GI) bleeding is a common complication of oral anticoagulation. OBJECTIVES: This study evaluated GI bleeding in patients who received at least 1 dose of the study drug in the on-treatment arm of the ROCKET AF (Rivaroxaban Once- ...
Full textLink to itemCite
Journal ArticleJ Am Heart Assoc · November 5, 2015
BACKGROUND: There is significant practice variation in oral anticoagulation (OAC) use following catheter ablation for atrial fibrillation. It is not clear whether the risk of cardioembolism increases after discontinuation of OAC following catheter ablation ...
Full textLink to itemCite
Journal ArticleAnesth Analg · October 2015
BACKGROUND: Hypomagnesemia has been associated with an increased risk of postoperative atrial fibrillation (POAF). Although previous studies have suggested a beneficial effect of magnesium (Mg) therapy, almost all of these are limited by small sample size ...
Full textLink to itemCite
Journal ArticleAm Heart J · October 2015
BACKGROUND: The prevalence of both atrial fibrillation (AF) and diabetes mellitus (DM) are rising, and these conditions often occur together. Also, DM is an independent risk factor for stroke in patients with AF. We aimed to examine the safety and efficacy ...
Full textLink to itemCite
Journal ArticleJ Am Heart Assoc · September 14, 2015
BACKGROUND: Most patients with atrial fibrillation (AF) require rate control; however, the optimal target heart rate remains under debate. We aimed to assess rate control and subsequent outcomes among patients with permanent AF. METHODS AND RESULTS: We stu ...
Full textOpen AccessLink to itemCite
Journal ArticleCardiovasc Ther · August 2015
AIMS: Oral anticoagulation therapy prevents stroke and improves survival in patients with atrial fibrillation, but the therapy is underutilized. We sought to identify the prevalence of contraindications for oral anticoagulation and the proportion of patien ...
Full textLink to itemCite
Journal ArticleCirc Cardiovasc Qual Outcomes · July 2015
BACKGROUND: Instruments to assess symptom burden and quality of life among patients with atrial fibrillation (AF) have not been well evaluated in community practice or associated with patient outcomes. METHODS AND RESULTS: Using data from 10 087 AF patient ...
Full textLink to itemCite
Journal ArticleAm Heart J · July 2015
BACKGROUND: Time in therapeutic range (TTR) of international normalized ratio (INR) of 2.0 to 3.0 is important for the safety and effectiveness of warfarin anticoagulation. There are few data on TTR among patients with atrial fibrillation (AF) in community ...
Full textLink to itemCite
Journal ArticleJ Am Coll Cardiol · June 30, 2015
BACKGROUND: Although digoxin has long been used to treat atrial fibrillation (AF) and heart failure (HF), its safety remains controversial. OBJECTIVES: This study sought to describe digoxin use over time in patients with AF who were stratified by the prese ...
Full textLink to itemCite
Journal ArticleJ Am Coll Cardiol · June 23, 2015
BACKGROUND: Remote monitoring (RM) technology embedded within cardiac rhythm devices permits continuous monitoring, which may result in improved patient outcomes. OBJECTIVES: This study used "big data" to assess whether RM is associated with improved survi ...
Full textLink to itemCite
Journal ArticleLancet · June 13, 2015
BACKGROUND: Digoxin is a widely used drug for ventricular rate control in patients with atrial fibrillation (AF), despite a scarcity of randomised trial data. We studied the use and outcomes of digoxin in patients in the Rivaroxaban Once Daily Oral Direct ...
Full textLink to itemCite
Journal ArticleJ Interv Card Electrophysiol · June 2015
PURPOSE: While the accuracy of roentography for evaluation of lead tip position compared with three-dimensional imaging techniques has been well described, there remains considerable variability in the interpretation of the reproducibility of standard x-ra ...
Full textLink to itemCite
Journal ArticleHeart · June 2015
OBJECTIVE: Atrial fibrillation (AF) often progresses from paroxysmal or persistent to more sustained forms, but the rate and predictors of AF progression in clinical practice are not well described. METHODS: Using the Outcomes Registry for Better Informed ...
Full textOpen AccessLink to itemCite
Journal ArticleAm Heart J · June 2015
BACKGROUND: Catheter ablation for atrial fibrillation is used increasingly in older patients, yet the risks and benefits are not completely understood. With such uncertainty, local medical opinion may influence catheter ablation use. METHODS: In a 100% sam ...
Full textLink to itemCite
Journal ArticleHeart Rhythm · June 2015
BACKGROUND: The Riata class of defibrillator leads were placed under US Food and Drug Association (FDA) advisory as of November 2011 because of high rates of cable externalization (CE) and electrical failure (EF). The overall rates of these complications r ...
Full textOpen AccessLink to itemCite
Journal ArticleExpert Rev Cardiovasc Ther · June 2015
Atrial fibrillation (AF) is the most prevalent cardiac arrhythmia and it increases the risk of thromboembolic stroke and death. AF is common in patients with heart failure and reduced ejection fraction (HFrEF), affecting between 30 and 40% of patients with ...
Full textLink to itemCite
Journal ArticleJ Am Heart Assoc · May 21, 2015
BACKGROUND: The characteristics of patients undergoing atrial fibrillation (AF) ablation and subsequent outcomes in community practice are not well described. METHODS AND RESULTS: Using the Outcomes Registry for Better Informed Treatment of Atrial Fibrilla ...
Full textOpen AccessLink to itemCite
Journal ArticleAm J Cardiol · May 15, 2015
Electrical cardioversion (ECV) is recommended for rhythm control in patients with atrial arrhythmia; yet, ECV use and outcomes in contemporary practice are unknown. We reviewed all nonemergent ECVs for atrial arrhythmias at a tertiary care center (2010 to ...
Full textLink to itemCite
Journal ArticleAm Heart J · May 2015
BACKGROUND: Obstructive sleep apnea (OSA) is common in patients with atrial fibrillation (AF). Little is known about the impact of OSA on AF treatment and long-term outcomes. We studied whether patients with OSA have a greater likelihood of progressing to ...
Full textLink to itemCite
Journal ArticleCirc Cardiovasc Qual Outcomes · May 2015
BACKGROUND: Antiarrhythmic drugs (AADs) are used to reduce the frequency, severity, and duration of atrial fibrillation (AF) events, which should reduce hospitalizations; however, little is known about the associations between different AADs and hospitaliz ...
Full textLink to itemCite
Journal ArticleJ Am Heart Assoc · March 3, 2015
BACKGROUND: In the ROCKET AF (Rivaroxaban-Once-daily, oral, direct Factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) trial, marked regional differences in control of warfarin anticoa ...
Full textLink to itemCite
Journal ArticleHeart Rhythm · March 2015
BACKGROUND: Implantable cardioverter-defibrillator (ICD) shocks are associated with increased anxiety, health care utilization, and potentially mortality. OBJECTIVE: The purpose of the Shock-Less Study was to determine if providing feedback reports to phys ...
Full textLink to itemCite
Journal ArticleCirculation · February 3, 2015
BACKGROUND: Temporary interruption of oral anticoagulation for procedures is often required, and some propose using bridging anticoagulation. However, the use and outcomes of bridging during oral anticoagulation interruptions in clinical practice are unkno ...
Full textOpen AccessLink to itemCite
Journal ArticleEur Heart J · February 1, 2015
AIM: Anticoagulation prophylaxis for stroke is recommended for at-risk patients with either persistent or paroxysmal atrial fibrillation (AF). We compared outcomes in patients with persistent vs. paroxysmal AF receiving oral anticoagulation. METHODS AND RE ...
Full textLink to itemCite
Journal ArticleJ Cardiovasc Electrophysiol · February 2015
INTRODUCTION: Riata and Riata ST implantable cardioverter-defibrillator (ICD) leads (St. Jude Medical, Sylmar, CA, USA) can develop conductor cable externalization and/or electrical failure. Optimal management of these leads remains unknown. METHODS AND RE ...
Full textOpen AccessLink to itemCite
Journal ArticleAm J Cardiol · February 1, 2015
Little is known in clinical practice about antiarrhythmic drug (AAD) use in patients with atrial fibrillation (AF) (particularly younger ones) who do not have structural heart disease. Using the MarketScan database, we identified patients <65 years without ...
Full textLink to itemCite
Journal ArticleAm J Cardiol · January 1, 2015
We aimed to characterize the hemodynamic progression of aortic stenosis (AS) in a contemporary unselected cohort of patients with preserved left ventricular ejection fraction. Current guidelines recommend echocardiographic surveillance of hemodynamic progr ...
Full textLink to itemCite
Journal ArticleJ Card Fail · January 2015
BACKGROUND: We sought to determine if outcomes with exercise training in heart failure (HF) vary according to ventricular pacing type. METHODS AND RESULTS: Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION) randomized ...
Full textLink to itemCite
Journal ArticleAm Heart J · January 2015
BACKGROUND: There is no universally accepted algorithm for identifying atrial fibrillation (AF) patients and stroke risk using electronic data for use in performance measures. METHODS: Patients with AF seen in clinic were identified based on International ...
Full textLink to itemCite
Journal ArticleEur Heart J · December 14, 2014
AIMS: We investigated clinical characteristics and outcomes of patients with significant valvular disease (SVD) in the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in ...
Full textLink to itemCite
Journal ArticleHeart Rhythm · December 2014
BACKGROUND: Battery failure is an uncommon complication of implantable cardioverter-defibrillators (ICDs), but unanticipated battery depletion can have life-threatening consequences. OBJECTIVE: The purpose of this study was to describe the prevalence of a ...
Full textLink to itemCite
Journal ArticleHeart · December 2014
OBJECTIVE: Catheter ablation of atrial fibrillation (AF) has become an increasingly safe and effective therapy. This has been partly attributed to the use of adjunctive imaging modalities. We aimed to describe the use and associated outcomes of periprocedu ...
Full textLink to itemCite
ConferenceCirc Heart Fail · November 2014
BACKGROUND: Cardiac resynchronization therapy with defibrillator (CRT-D) reduces morbidity and mortality among selected patients with heart failure in clinical trials. The effectiveness of this therapy in clinical practice has not been well studied. METHOD ...
Full textLink to itemCite
Journal ArticleJ Cardiovasc Electrophysiol · November 2014
INTRODUCTION: Heart failure patients with left ventricular assist devices (LVADs) are at risk for infection. Cardiac implantable electronic devices (CIEDs) are commonly present in these patients. The course of infections in patients with an LVAD and a CIED ...
Full textLink to itemCite
Journal ArticleAm Heart J · October 2014
BACKGROUND: Warfarin reduces thromboembolic risks in atrial fibrillation (AF), but therapeutic durability remains a concern. METHODS: We used clinical data from ORBIT-AF, a nationwide outpatient AF registry conducted at 176 sites with follow-up data at 6 a ...
Full textLink to itemCite
Journal ArticlePacing Clin Electrophysiol · October 2014
BACKGROUND: Preprocedural multidetector computed tomography (MDCT) may identify patients at risk for mechanical complications during lead extraction. METHODS: To describe the use and feasibility of computed tomography scanning for preprocedural planning of ...
Full textLink to itemCite
Journal ArticleEuropace · September 2014
AIMS: Atrial fibrillation (AF) and coronary artery disease (CAD) are common in older patients. We aimed to describe the use of antiarrhythmic drug (AAD) therapy and clinical outcomes in these patients. METHODS AND RESULTS: We analysed AAD therapy and outco ...
Full textLink to itemCite
Journal ArticleAm J Cardiol · September 1, 2014
Sotalol is a commonly prescribed antiarrhythmic drug (AAD) used for maintaining sinus rhythm in patients with atrial fibrillation (AF). Although randomized studies have found that sotalol can significantly delay time to AF recurrence, its association with ...
Full textLink to itemCite
Journal ArticleCirc Cardiovasc Qual Outcomes · September 2014
BACKGROUND: Patients with heart failure and atrial fibrillation are at higher risk of thromboembolic events than patients with heart failure alone. Yet, the use of anticoagulation therapy varies in clinical practice, especially among older patients, for wh ...
Full textLink to itemCite
Journal ArticleCirc Cardiovasc Qual Outcomes · September 2014
BACKGROUND: Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia. It is a cause of stroke, heart failure, and death. Guideline-based treatment can improve outcomes in AF. Unfortunately, adherence to these guidelines is low. Get With The ...
Full textLink to itemCite
Journal ArticleJ Am Coll Cardiol · August 19, 2014
Because nonpharmacological interventions likely alter the risks and benefits associated with rhythm control, this paper reviews the role of current rhythm control strategies in atrial fibrillation. This report also focuses on the specific limitations of ph ...
Full textLink to itemCite
Journal ArticleAm Heart J · August 2014
BACKGROUND: Recent clinical trials have demonstrated the safety and efficacy of several non-vitamin K oral anticoagulants (NOACs) for the treatment of atrial fibrillation (AF). However, there are limited data on their use and outcomes in routine clinical p ...
Full textLink to itemCite
Journal ArticleEur Heart J · July 21, 2014
AIMS: There are no data regarding management and outcomes of major bleeding events in patients treated with oral factor Xa inhibitors. METHODS AND RESULTS: Using data from ROCKET AF, we analysed the management and outcomes of major bleeding overall and acc ...
Full textLink to itemCite
Journal ArticleAm J Cardiol · July 15, 2014
Cardiovascular imaging is an important part of procedural planning and safety for catheter ablation of atrial fibrillation (AF). However, the costs of imaging surrounding catheter ablation of AF have not been described. Medicare fee-for-service data were u ...
Full textLink to itemCite
Journal ArticleCirculation · July 8, 2014
BACKGROUND: Nonvalvular atrial fibrillation is common in elderly patients, who face an elevated risk of stroke but difficulty sustaining warfarin treatment. The oral factor Xa inhibitor rivaroxaban was noninferior to warfarin in the Rivaroxaban Once Daily, ...
Full textLink to itemCite
Journal ArticleHeart Rhythm · June 2014
BACKGROUND: Antiarrhythmic drugs (AADs) and anticoagulation are mainstays of atrial fibrillation (AF) treatment. OBJECTIVE: To study the use and outcomes of AAD therapy in anticoagulated patients with AF. METHODS: Patients in the Rivaroxaban Once Daily Ora ...
Full textLink to itemCite
Journal ArticleCirculation · May 20, 2014
BACKGROUND: Physicians treating patients with atrial fibrillation (AF) must weigh the benefits of anticoagulation in preventing stroke versus the risk of bleeding. Although empirical models have been developed to predict such risks, the degree to which the ...
Full textLink to itemCite
Journal ArticleCirculation · May 6, 2014
BACKGROUND: During long-term anticoagulation in atrial fibrillation, temporary interruptions (TIs) of therapy are common, but the relationship between patient outcomes and TIs has not been well studied. We sought to determine reasons for TI, the characteri ...
Full textLink to itemCite
Journal ArticleAnn Intern Med · May 6, 2014
BACKGROUND: Trials comparing implantable cardioverter-defibrillator (ICD) therapy with cardiac resynchronization therapy with a defibrillator (CRT-D) are limited to selected patients treated at centers with extensive experience. OBJECTIVE: To compare outco ...
Full textLink to itemCite
Journal ArticleAm Heart J · May 2014
BACKGROUND: Atrial fibrillation (AF) is the most common cardiac dysrhythmia and contributes significantly to health care expenditures. We sought to assess the frequency and predictors of hospitalization in patients with AF. METHODS: The ORBIT-AF registry i ...
Full textLink to itemCite
Journal ArticleStroke · May 2014
BACKGROUND AND PURPOSE: Intracranial hemorrhage (ICH) is a life-threatening complication of anticoagulation. METHODS: We investigated the rate, outcomes, and predictors of ICH in 14 264 patients with atrial fibrillation from Rivaroxaban Once Daily, Oral, D ...
Full textLink to itemCite
Journal ArticleJ Am Heart Assoc · April 22, 2014
BACKGROUND: Time in therapeutic range (TTR) is a standard quality measure of the use of warfarin. We assessed the relative effects of rivaroxaban versus warfarin at the level of trial center TTR (cTTR) since such analysis preserves randomized comparisons. ...
Full textLink to itemCite
Journal ArticleBMJ · April 14, 2014
Atrial fibrillation increases the risk of stroke, which is a leading cause of death and disability worldwide. The use of oral anticoagulation in patients with atrial fibrillation at moderate or high risk of stroke, estimated by established criteria, improv ...
Full textLink to itemCite
Journal ArticleAm Heart J · April 2014
BACKGROUND: Oral anticoagulation (OAC) therapy reduces the risk of thromboembolic events associated with atrial fibrillation (AF), yet a substantial proportion of patients with AF are not prescribed OAC. The aim of this study is to describe the frequencies ...
Full textLink to itemCite
Journal ArticleJ Am Coll Cardiol · March 11, 2014
OBJECTIVES: This study sought to report additional safety results from the ROCKET AF (Rivaroxaban Once-daily oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation). BACKGROUND ...
Full textLink to itemCite
Journal ArticleJACC Heart Fail · February 2014
OBJECTIVES: This study sought to examine the long-term outcomes of patients hospitalized with heart failure and atrial fibrillation. BACKGROUND: Atrial fibrillation is common among patients hospitalized with heart failure. Associations of pre-existing and ...
Full textLink to itemCite
Journal ArticleEur Heart J · January 2014
AIMS: Atrial fibrillation increases the risks of stroke, heart failure, and death, and anticoagulation therapy increases the risk of gastrointestinal haemorrhage. However, the relative event rates for these outcomes are not well described. We sought to def ...
Full textLink to itemCite
Journal ArticleEur Heart J · January 2014
AIMS: Vascular disease is included in a risk scoring system to predict stroke in patients with non-valvular atrial fibrillation (AF). This post hoc analysis of ROCKET AF aimed to determine the absolute rates of stroke and bleeding, and the relative effecti ...
Full textLink to itemCite
Journal ArticleClin Cardiol · January 2014
BACKGROUND: Postoperative atrial fibrillation (POAF) is a well-recognized complication of cardiac surgery; however, its management remains a challenge, and the implementation and outcomes of various strategies in clinical practice remain unclear. HYPOTHESI ...
Full textLink to itemCite
Journal ArticleEur Heart J · January 2014
AIMS: We investigated the prevalence of prior myocardial infarction (MI) and incidence of ischaemic cardiovascular (CV) events among atrial fibrillation (AF) patients. METHODS AND RESULTS: In ROCKET AF, 14 264 patients with nonvalvular AF were randomized t ...
Full textLink to itemCite
ConferenceJournal of the American Heart Association · January 1, 2014
Background: Time in therapeutic range (TTR) is a standard quality measure of the use of warfarin. We assessed the relative effects of rivaroxaban versus warfarin at the level of trial center TTR (cTTR) since such analysis preserves randomized comparisons. ...
Full textCite
Journal ArticleJournal of Atrial Fibrillation · December 1, 2013
The risks and benefits of anticoagulation for patients with both heart failure and atrial fibrillation are unclear. We hypothesized that anticoagulation was associated with improved clinical outcomes of heart failure patients with atrial fibrillation indep ...
Cite
Journal ArticleJ Atr Fibrillation · December 2013
The risks and benefits of anticoagulation for patients with both heart failure and atrial fibrillation are unclear. We hypothesized that anticoagulation was associated with improved clinical outcomes of heart failure patients with atrial fibrillation indep ...
Full textLink to itemCite
Journal ArticleJ Am Heart Assoc · November 25, 2013
BACKGROUND: Dabigatran is a novel oral anticoagulant approved for thromboprophylaxis in atrial fibrillation. Adoption patterns of this new agent in community practice are unknown. METHODS AND RESULTS: We studied patterns of dabigatran use among patients en ...
Full textOpen AccessLink to itemCite
Journal ArticleAm Heart J · November 2013
BACKGROUND: We sought to determine the risk of readmission for bleeding and major cardiac events in stented non-ST-segment elevation myocardial infarction (NSTEMI) atrial fibrillation (AF) patients. METHODS: For this patient population, selection of an ant ...
Full textLink to itemCite
Journal ArticleAm J Cardiol · October 1, 2013
Risk of atrial fibrillation (AF) after coronary artery bypass grafting (CABG) is high, yet the effectiveness of guideline-recommended preoperative prophylaxis in clinical practice remains uncertain. We determined the utilization and variation of preoperati ...
Full textLink to itemCite
Journal ArticleJ Am Heart Assoc · September 26, 2013
BACKGROUND: The intersection of heart failure (HF) and atrial fibrillation (AF) is common, but the burden of AF among black patients with HF is poorly characterized. We sought to determine the prevalence of AF, characteristics, in-hospital outcomes, and wa ...
Full textOpen AccessLink to itemCite
Journal ArticleJ Interv Card Electrophysiol · September 2013
PURPOSE: Dabigatran is approved for prevention of stroke or systemic embolism in patients with nonvalvular atrial fibrillation (AF). The safety and effectiveness of periprocedural dabigatran in ablation for AF are unknown. METHODS: We performed a meta-anal ...
Full textLink to itemCite
Journal ArticleJAMA · August 14, 2013
IMPORTANCE: The benefits of cardiac resynchronization therapy (CRT) in clinical trials were greater among patients with left bundle-branch block (LBBB) or longer QRS duration. OBJECTIVE: To measure associations between QRS duration and morphology and outco ...
Full textLink to itemCite
Journal ArticleCirculation · August 13, 2013
BACKGROUND: The role of concomitant aspirin (ASA) therapy in patients with atrial fibrillation (AF) receiving oral anticoagulation (OAC) is unclear. We assessed concomitant ASA use and its association with clinical outcomes among AF patients treated with O ...
Full textLink to itemCite
Journal ArticleJ Am Heart Assoc · July 18, 2013
BACKGROUND: The prevalence of atrial fibrillation (AF) continues to increase; however, there are limited data describing the division of care among practitioners in the community and whether care differs depending on provider specialty. METHODS AND RESULTS ...
Full textOpen AccessLink to itemCite
Journal ArticleCirc Cardiovasc Qual Outcomes · July 2013
BACKGROUND: To evaluate the previously reported excess of thromboembolic events during the 30 days after the end of study (EOS) visit when participants transitioned from blinded therapy to open-label vitamin K antagonist. METHODS AND RESULTS: At the EOS vi ...
Full textLink to itemCite
Journal ArticleAm J Med · July 2013
BACKGROUND: Patients with atrial fibrillation often have cardiovascular risk factors or known comorbid disease, yet the use of evidence-based primary and secondary prevention cardiac therapy among atrial fibrillation outpatients is unknown. METHODS: Using ...
Full textLink to itemCite
Journal ArticleHeart Fail Clin · July 2013
Hospitalization for heart failure (HHF) is commonly associated with symptomatic improvement in response to standard medical therapy, yet there remains a substantial risk of rehospitalization and death. Clinically stable outpatients and decompensated inpati ...
Full textLink to itemCite
Journal ArticleHeart Fail Clin · July 2013
Improved utilization and optimization of device therapy in the management of patients with decompensated heart failure (HF) is an important clinical priority. Diagnostic cardiac rhythm device data have been shown to predict hospitalization for HF. Cardiac ...
Full textLink to itemCite
Journal ArticleCirc Cardiovasc Qual Outcomes · July 2013
BACKGROUND: Patients with atrial fibrillation (AF) at the highest stroke risk derive the largest benefit from oral anticoagulation (OAC). Those with the highest stroke risk have been paradoxically less likely to receive OAC. This study assessed the associa ...
Full textLink to itemCite
Journal ArticleAnn Intern Med · June 18, 2013
BACKGROUND: In ROCKET AF (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation), a large randomized, clinical trial, rivaroxaban was noninferior to w ...
Full textLink to itemCite
Journal ArticleHeart Rhythm · June 2013
BACKGROUND: Whether there is an optimal time to place an implantable cardioverter-defibrillator (ICD) more than 40 days after myocardial infarction (MI) in guideline-eligible patients is unknown. OBJECTIVE: To evaluate the effect of time from MI to randomi ...
Full textLink to itemCite
Journal ArticleAm Heart J · June 2013
BACKGROUND: Newly diagnosed atrial fibrillation (AF) during severe sepsis is associated with increased risks of in-hospital stroke and mortality. However, the prevalence, incidence, and risk factors associated with AF during the sepsis syndromes are unclea ...
Full textLink to itemCite
Journal ArticleJ Am Coll Cardiol · May 14, 2013
OBJECTIVES: This study sought to investigate the outcomes following cardioversion or catheter ablation in patients with atrial fibrillation (AF) treated with warfarin or rivaroxaban. BACKGROUND: There are limited data on outcomes following cardioversion or ...
Full textLink to itemCite
Journal ArticlePacing Clin Electrophysiol · May 2013
BACKGROUND: Proper positioning of the left ventricular (LV) lead improves clinical outcomes and survival in patients receiving cardiac resynchronization therapy (CRT). Techniques of LV lead insertion using contrast injection and a telescoping system of del ...
Full textLink to itemCite
Journal ArticleAm Heart J · April 2013
BACKGROUND: All patients with atrial fibrillation (AF) require optimization of their ventricular rate. Factors leading to use of additional rhythm control in clinical practice have not been thoroughly defined. METHODS: The ORBIT-AF registry enrolled patien ...
Full textLink to itemCite
Journal ArticleJACC Heart Fail · April 2013
OBJECTIVES: The purpose of this study was to determine whether exercise training is associated with an increased risk of implantable cardioverter-defibrillator (ICD) therapy in patients with heart failure (HF). BACKGROUND: Few data are available regarding ...
Full textLink to itemCite
Journal Article · March 21, 2013
Cardiac sarcoidosis can present as ventricular ectopy, sustained ventricular arrhythmias, asymptomatic ventricular dysfunction, heart failure, or sudden death. Although 25% of patients with sarcoidosis have evidence of cardiac involvement autopsy, only 5% ...
Full textCite
Journal ArticleJ Am Heart Assoc · February 19, 2013
BACKGROUND: Vitamin K antagonist (VKA) therapy remains the most common method of stroke prevention in patients with atrial fibrillation. Time in therapeutic range (TTR) is a widely cited measure of the quality of VKA therapy. We sought to identify factors ...
Full textLink to itemCite
Journal ArticleJ Am Coll Cardiol · February 12, 2013
OBJECTIVES: The purpose of this study was to understand the possible risk of discontinuation in the context of clinical care. BACKGROUND: Rivaroxaban is noninferior to warfarin for preventing stroke in atrial fibrillation patients. Concerns exist regarding ...
Full textLink to itemCite
Journal ArticleCirculation · January 15, 2013
BACKGROUND: We sought to define the factors associated with the occurrence of stroke and systemic embolism in a large, international atrial fibrillation (AF) trial. METHODS AND RESULTS: In ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibitio ...
Full textLink to itemCite
Journal ArticleAm Heart J · November 2012
Transcatheter aortic valve replacement (TAVR) is a rapidly-evolving technology for patients with severe, calcific aortic stenosis. Although these procedures lessen many of the risks and complications of open surgical aortic valve replacement, there remain ...
Full textLink to itemCite
Journal ArticleCirculation · October 30, 2012
BACKGROUND: Atrial fibrillation is common among older persons. Catheter ablation is increasingly used in patients for whom medical therapy has failed. METHODS AND RESULTS: We conducted a retrospective cohort study of all fee-for-service Medicare beneficiar ...
Full textLink to itemCite
Journal ArticleClin Cardiol · October 2012
BACKGROUND: Guidelines recommend evaluation of cardiac function, valvular and ischemic heart disease, and thyroid, kidney, and liver function on initial diagnosis of atrial fibrillation (AF). HYPOTHESIS: We hypothesized that initial workup of patients with ...
Full textLink to itemCite
Journal ArticleAm Heart J · October 2012
BACKGROUND: Older patients with atrial fibrillation (AF) and coronary artery disease (CAD) face high risk of stroke and bleeding with antithrombotic therapy. Balancing safe and effective use of aspirin, clopidogrel, and warfarin in this population is impor ...
Full textLink to itemCite
Journal ArticleJournal of Atrial Fibrillation · October 1, 2012
Atrial fibrillation frequently complicates myocardial infarction. Patients with atrial fibrillation complicating acute coronary syndrome have increased morbidity and mortality relative to patients that remain in normal sinus rhythm. No studies have identif ...
Cite
Journal ArticleHeart Rhythm · September 2012
BACKGROUND: There are limited data regarding national patterns of pharmacotherapy for atrial fibrillation (AF) among older patients. Drug exposure data are now captured for Medicare beneficiaries enrolled in prescription drug plans. OBJECTIVE: To describe ...
Full textLink to itemCite
Journal ArticleCirculation · July 3, 2012
BACKGROUND: Ventricular arrhythmias remain a lethal complication of acute coronary syndromes (ACS). However, the incidence and prognosis of sustained ventricular tachycardia/ventricular fibrillation (VT/VF) in contemporary non-ST-segment-elevation (NSTE) A ...
Full textLink to itemCite
Journal ArticleAm Heart J · May 2012
BACKGROUND: We sought to characterize patient factors and regional variations associated with vitamin K antagonist (VKA) use in patients with heart failure (HF) and atrial fibrillation (AF) in areas outside the United States and Europe. METHODS: The ADHERE ...
Full textLink to itemCite
Journal ArticleJ Vasc Surg · May 2012
OBJECTIVE: Retrograde ascending aortic dissection (rAAD) is a potential complication of thoracic endovascular aortic repair (TEVAR), yet little data exist regarding its occurrence. This study examines the incidence, etiology, and outcome of this event. MET ...
Full textLink to itemCite
Journal ArticleAm Heart J · April 2012
BACKGROUND: We aimed to study the comparative safety and effectiveness of various antithrombotic treatment strategies among older adults with non-ST elevation myocardial infarction (NSTEMI) and atrial fibrillation (AF). METHODS: Using the CRUSADE registry ...
Full textLink to itemCite
Journal ArticleAm J Cardiol · March 15, 2012
The prognostic significance of postprocedure sustained ventricular tachycardia or ventricular fibrillation (VT/VF) in patients undergoing primary percutaneous coronary intervention (PPCI) for ST-segment elevation myocardial infarction (STEMI) has rarely be ...
Full textLink to itemCite
Journal ArticleJ Atr Fibrillation · 2012
Atrial fibrillation frequently complicates myocardial infarction. Patients with atrial fibrillation complicating acute coronary syndrome have increased morbidity and mortality relative to patients that remain in normal sinus rhythm. No studies have identif ...
Full textLink to itemCite
Journal ArticleCirc Cardiovasc Qual Outcomes · January 2012
BACKGROUND: Atrial fibrillation (AF) is a common and costly problem among older persons. The frequency of AF increases with age, but representative national data about incidence and prevalence are limited. We examined the annual incidence, prevalence, and ...
Full textLink to itemCite
Journal ArticleEuropace · December 2011
AIMS: Chronic kidney disease (CKD) is increasingly prevalent, and is an independent risk factor for cardiovascular mortality. Clinical trials of the implantable cardioverter-defibrillator (ICD) have demonstrated a survival benefit over medical therapy for ...
Full textLink to itemCite
Journal ArticleJ Interv Card Electrophysiol · December 2011
Atrial fibrillation (AF) is a significant burden to the public health. AF is associated with increased morbidity and mortality, including an increased risk of heart failure, stroke, cognitive impairment, and diminished quality of life. Catheter ablation is ...
Full textLink to itemCite
Journal ArticleJ Cardiovasc Electrophysiol · October 2011
Featured Publication
Use of VSTAP to Facilitate Hemodynamic Support. The ablation of hemodynamically unstable ventricular tachycardia (VT) is challenging and frequently requires alternative mapping techniques or the use of percutaneous mechanical support devices. Loss of atrio ...
Full textLink to itemCite
Journal ArticleAm Heart J · October 2011
BACKGROUND: Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia and is associated with an increased risk of stroke, heart failure, and death. Data on contemporary treatment patterns and outcomes associated with AF in clinical practice ...
Full textLink to itemCite
Journal ArticleEur Heart J · October 2011
AIMS: Patients with non-valvular atrial fibrillation (AF) and renal insufficiency are at increased risk for ischaemic stroke and bleeding during anticoagulation. Rivaroxaban, an oral, direct factor Xa inhibitor metabolized predominantly by the liver, prese ...
Full textLink to itemCite
Journal ArticleN Engl J Med · September 8, 2011
BACKGROUND: The use of warfarin reduces the rate of ischemic stroke in patients with atrial fibrillation but requires frequent monitoring and dose adjustment. Rivaroxaban, an oral factor Xa inhibitor, may provide more consistent and predictable anticoagula ...
Full textLink to itemCite
Journal ArticleHeart Fail Rev · September 2011
Implantable cardioverter-defibrillators have proven efficacy in reducing mortality in patients with reduced left ventricular ejection fraction in both the primary and the secondary prevention settings. All randomized trials demonstrating this benefit have ...
Full textLink to itemCite
Journal ArticleJ Am Coll Cardiol · August 23, 2011
Heart failure (HF) and chronic kidney disease (CKD) both carry significant risk for sudden cardiac death, hospitalization, and mortality; when combined, however, they markedly increase the risk of morbidity and mortality. Device therapies such as implantab ...
Full textLink to itemCite
Journal ArticleAm Heart J · April 2011
BACKGROUND: The association of sustained ventricular tachycardia/fibrillation (VT/VF) with mortality in patients undergoing primary percutaneous coronary intervention (PCI) may vary with baseline patient risk and may be associated with higher mortality in ...
Full textLink to itemCite
Journal ArticleCirc Cardiovasc Genet · April 2011
BACKGROUND: Risk-stratifying heart failure patients for primary prevention implantable cardioverter-defibrillators (ICDs) remains a challenge, especially for blacks, who have an increased incidence of sudden cardiac death but have been underrepresented in ...
Full textLink to itemCite
Journal ArticleHeart Rhythm · March 2011
Featured Publication
BACKGROUND: The implantable cardioverter-defibrillator (ICD) is an effective therapy for preventing sudden cardiac death (SCD) in patients with prior myocardial infarction (MI) and reduced left ventricular function; however, the optimal timing of ICD impla ...
Full textLink to itemCite
Journal ArticleCirc Cardiovasc Qual Outcomes · March 2011
BACKGROUND: Several studies that used claims and registry data have reported that 40% to 80% of patients eligible for an implantable cardioverter defibrillator (ICD) fail to receive one in clinical practice, and the rates are especially high among women an ...
Full textLink to itemCite
Journal ArticleEuropace · February 2011
AIMS: Although useful, percutaneous left atrial ablation for pulmonary vein isolation (PVI) does not eliminate atrial fibrillation (AF) in all patients. The ablation of complex fractionated atrial electrograms (CFAEs) has been proposed as an adjunctive str ...
Full textLink to itemCite
Journal ArticleCrit Care Med · January 2011
Featured Publication
OBJECTIVE: Few data exist to guide antiarrhythmic drug therapy for sustained ventricular tachycardia/ventricular fibrillation after acute myocardial infarction. The objective of this analysis was to describe the survival of patients with sustained ventricu ...
Full textLink to itemCite
Journal ArticleClinics (Sao Paulo) · 2011
OBJECTIVES: N-3 polyunsaturated fatty acids have been proposed as a novel treatment for preventing postoperative atrial fibrillation due to their potential anti-inflammatory and anti-arrhythmic effects. However, randomized studies have yielded conflicting ...
Full textLink to itemCite
Journal ArticleCardiovasc Ther · October 2010
Surgical or modified Maze procedures have been promoted to treat atrial fibrillation (AF); however, few randomized controlled clinical trials (RCTs) examine their outcomes. The purpose of this meta-analysis is to compare the efficacy of surgical Maze proce ...
Full textLink to itemCite
Journal ArticleCirculation · September 21, 2010
BACKGROUND: The role of implantable cardioverter-defibrillator (ICD) in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia and no prior ventricular fibrillation (VF) or sustained ventricular tachycardia is an unsolved issue. METHODS AN ...
Full textLink to itemCite
Journal ArticleJ Am Coll Cardiol · July 13, 2010
Featured Publication
OBJECTIVES: The aim of this study was to determine whether single-photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI) is an effective method of risk stratification for sudden cardiac death (SCD) in patients with coronary artery d ...
Full textLink to itemCite
Journal ArticleCurr Opin Cardiol · July 2010
PURPOSE OF REVIEW: Prevention of stroke and systemic emboli is paramount in the management of atrial fibrillation. Although warfarin is the predominant anticoagulant used in patients with atrial fibrillation, it has significant limitations that have impede ...
Full textLink to itemCite
Journal ArticleJ Cardiovasc Electrophysiol · July 2010
Featured Publication
BACKGROUND: The optimal timing of implantable cardioverter defibrillator (ICD) placement for the primary prevention of sudden cardiac death after myocardial infarction (MI) remains unknown. METHODS AND RESULTS: We developed a Markov model to investigate th ...
Full textLink to itemCite
Journal ArticleJ Cardiovasc Electrophysiol · May 2010
INTRODUCTION: Remote monitoring is increasingly becoming the new standard of care for implantable cardioverter defibrillator (ICD) follow-up. We sought to determine whether remote monitoring of ICDs improves patient outcomes compared with quarterly device ...
Full textLink to itemCite
Journal ArticleEur Heart J · January 2010
Featured Publication
AIMS: To determine whether predictors of sudden cardiac death (SCD) vary with time after myocardial infarction (MI). METHODS AND RESULTS: We analysed 11 256 patients enrolled in VALIANT. Landmark analysis and Cox proportional hazards modelling were used to ...
Full textLink to itemCite
Journal ArticleAm J Ther · 2010
The aim of this study was to investigate the association between implantable cardioverter-defibrillator (ICD) status at the time of hospitalization for worsening heart failure (HF) with postdischarge events in patients with reduced left ventricular ejectio ...
Full textLink to itemCite
Journal ArticleCirc Arrhythm Electrophysiol · December 2009
Featured Publication
BACKGROUND: Catheter ablation is an established yet evolving nonpharmacologic intervention for the maintenance of sinus rhythm in patients with atrial fibrillation (AF). The efficacy and safety of pulmonary vein isolation (PVI) compared with medical therap ...
Full textLink to itemCite
Journal ArticleAm Heart J · November 2009
BACKGROUND: Disturbances in cardiac rhythm can lead to significant morbidity and mortality. Many arrhythmias are known to have a heritable component, but the degree to which genetic variation contributes to disease risk and morbidity is poorly understood. ...
Full textLink to itemCite
Journal ArticleJ Am Coll Cardiol · September 29, 2009
Featured Publication
OBJECTIVES: This study sought to examine quality of care and warfarin use at discharge in patients with atrial fibrillation (AF) and heart failure (HF). BACKGROUND: Atrial fibrillation is common in HF, and national guidelines recommend discharge on warfari ...
Full textLink to itemCite
Journal ArticleJ Am Coll Cardiol · September 15, 2009
Featured Publication
OBJECTIVES: We sought to compare the efficacy and safety of dronedarone versus amiodarone for the prevention of recurrent atrial fibrillation (AF). BACKGROUND: Dronedarone is a noniodinated amiodarone congener developed to maintain sinus rhythm. Few data a ...
Full textLink to itemCite
Journal ArticleAm Heart J · September 2009
In October 2008, in a public forum organized by the Cardiac Safety Research Consortium and the Health and Environmental Sciences Institute, leaders from government, the pharmaceutical industry, and academia convened in Bethesda, MD, to discuss current chal ...
Full textLink to itemCite
Journal ArticleJ Cardiovasc Electrophysiol · August 2009
INTRODUCTION: Programmed stimulation is an important prognostic tool in the evaluation of patients with an ejection fraction
Full textLink to itemCite
Journal ArticleClin Pharmacol Ther · July 2009
The cardiovascular safety of new drugs is an overarching concern for all stakeholders: the pharmaceutical industry and the US Food and Drug Administration (FDA) prior to approval and doctors and patients during postrelease drug use. Of the many cardiac saf ...
Full textLink to itemCite
Journal ArticleEur Heart J · May 2009
AIMS: Not all patients at risk for sudden cardiac death (SCD) are eligible for, or have access to implantable cardioverter defibrillator (ICD) implantation. There are conflicting data regarding the efficacy and safety of amiodarone for the prevention of SC ...
Full textLink to itemCite
Journal ArticleJ Nucl Cardiol · 2009
BACKGROUND: A 17-segment model has become the standard for interpreting myocardial perfusion single-photon emission computed tomography (SPECT). Methods for converting pre-existing databases from 12-segment models to the 17-segment model are needed for ong ...
Full textLink to itemCite
Journal ArticleJ Thromb Thrombolysis · December 2008
Atrial fibrillation (AF) is the most common cardiac arrhythmia in clinical practice, accounting for approximately one-third of hospitalizations for cardiac rhythm disturbances. The highest incidence of AF is in patients 70-80 years old and other high-risk ...
Full textLink to itemCite
Journal ArticleAm J Cardiol · December 1, 2008
Sustained ventricular arrhythmias and heart failure are well-recognized complications after acute myocardial infarction (AMI) and have been associated with worse outcomes and increased mortality. The use of and outcomes associated with acute beta-blocker t ...
Full textLink to itemCite
Journal ArticleCirc Cardiovasc Imaging · November 2008
BACKGROUND: Single-photon emission computed tomography myocardial perfusion imaging defects are associated with increased all-cause mortality and cardiovascular death. However, it is unknown whether single-photon emission computed tomography myocardial per ...
Full textLink to itemCite
Journal ArticleAm J Med · September 2008
OBJECTIVE: Sustained ventricular arrhythmias complicate 2% to 20% of acute myocardial infarctions (MIs) and are associated with increased in-hospital mortality. However, it remains unclear whether successful mechanical revascularization improves outcomes i ...
Full textLink to itemCite
Journal ArticleCirculation · August 26, 2008
Featured Publication
BACKGROUND: The frequency and characterization of patients receiving cardiac resynchronization therapy (CRT) are largely unknown since the publication of pivotal clinical trials and subsequent incorporation of CRT into the American College of Cardiology/Am ...
Full textLink to itemCite
Journal ArticleExpert Opin Investig Drugs · June 2008
Rivaroxaban is a small molecule, direct Factor Xa inhibitor and may be a potentially attractive alternative to vitamin K antagonists. Rivaroxaban is being investigated for the prevention and treatment of venous and arterial thrombosis. A broad search of Me ...
Full textLink to itemCite
Journal ArticleJ Urol · July 2007
PURPOSE: We determined the efficacy of a combination of corticosteroids and mycophenolate mofetil for retroperitoneal fibrosis. MATERIALS AND METHODS: We performed a prospective observational study of the treatment of 7 patients with biopsy proven retroper ...
Full textLink to itemCite
Journal ArticleAm J Cardiol · July 1, 2007
The purpose of this study was to report 1 center's experience with multidetector computed tomography (MDCT) in the evaluation of patients suspected to have arrhythmogenic right ventricular (RV) dysplasia/cardiomyopathy (ARVD/C). RV dilatation/dysfunction i ...
Full textLink to itemCite
Journal ArticleAm Heart J · April 2007
Heart failure affects 5 million Americans and is associated with a tremendous economic burden, leading to 26.7 billion dollars in health care expenditures each year (American Heart Association, American Stroke Association. Heart disease and stroke statisti ...
Full textLink to itemCite
Journal ArticleCirculation · April 4, 2006
BACKGROUND: Arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C) is an inherited cardiomyopathy characterized by right ventricular dysfunction and ventricular arrhythmias. A recent study reported mutations in PKP2, encoding the desmosomal pro ...
Full textLink to itemCite
Journal ArticleCirculation · December 20, 2005
BACKGROUND: Arrhythmogenic right ventricular dysplasia (ARVD) is an inherited cardiomyopathy characterized by right ventricular dysfunction and ventricular arrhythmias. The purpose of our study was to describe the presentation, clinical features, survival, ...
Full textLink to itemCite
Journal ArticleHeart Rhythm · November 2005
Featured Publication
BACKGROUND: Arrhythmogenic right ventricular dysplasia (ARVD) is an inherited cardiomyopathy characterized by ventricular arrhythmias and sudden cardiac death. The risk factors for sudden death and indications for implantable cardioverter-defibrillator (IC ...
Full textLink to itemCite
Journal ArticleAm J Cardiol · July 1, 2005
Featured Publication
Thirty-five patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy underwent serial electrocardiographic (ECG) testing and were evaluated for evidence of ECG progression. Over a median of 43 months, 89% of the patients had evidence of prog ...
Full textLink to itemCite
Journal ArticleAm J Med · March 8, 2004
Heart failure affects nearly 5 million people in the United States and is a major contributor to mortality, hospitalization, and medical costs. Approximately 40% of patients with heart failure have preserved left ventricular systolic function, thus exhibit ...
Full textLink to itemCite
Journal ArticleImmunology · December 2000
Chicken antibodies (immunoglobulin Y; IgY) to the alpha Gal epitope (galactose alpha-1,3-galactose) bind to alpha Gal antigens of mouse and porcine tissues and endothelial cells in vitro and block human anti-alpha Gal antibody binding, complement activatio ...
Full textLink to itemCite
Journal ArticleVis Neurosci · 1998
ninaE(D1), a dominant allele of the major Drosophila rhodopsin gene, expresses a rhodopsin that is predominantly recovered in a 80-kD complex that likely represents rhodopsin dimers. By driving either ninaE(D1) or ninaE+ expression from a heat-shock promot ...
Full textLink to itemCite
